


525 Rec'd PCT/PTO 22 NOV 2000

FORM PTO-1390 (Modified) (REV 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				081356/0154	
INTERNATIONAL APPLICATION NO. PCT/JP99/02644		INTERNATIONAL FILING DATE May 20, 1999		U.S. APPLICATION NO. (if known) <b>097700993</b> Unassigned	
TITLE OF INVENTION ENDO-β-N-ACETYLGLUCOSAMINIDASE GENE		PRIORITY DATE CLAIMED May 22, 1998			
APPLICANT(S) FOR DO/EO/US Kazuo KOBAYASHI, Makoto TAKEUCHI, Akihiko IWAMATSU, Satoshi YOSHIDA, Kenji YAMAMOTO, Hidehiko KUMAGAI					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1.	<input checked="" type="checkbox"/>	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.			
2.	<input type="checkbox"/>	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.			
3.	<input type="checkbox"/>	This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).			
4.	<input checked="" type="checkbox"/>	A proper Demand for International Preliminary Examination was made by the 19 <sup>th</sup> month from the earliest claimed priority date.			
5.	<input checked="" type="checkbox"/>	A copy of the International Application as filed (35 U.S.C. 371(c)(2))			
	<input type="checkbox"/>	is transmitted herewith (required only if not transmitted by the International Bureau).			
	<input checked="" type="checkbox"/>	has been transmitted by the International Bureau.			
	<input type="checkbox"/>	is not required, as the application was filed in the United States Receiving Office (RO/US)			
6.	<input checked="" type="checkbox"/>	A translation of the International Application into English (35 U.S.C. 371(c)(2)).			
7.	<input checked="" type="checkbox"/>	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))			
	<input type="checkbox"/>	are transmitted herewith (required only if not transmitted by the International Bureau).			
	<input type="checkbox"/>	have been transmitted by the International Bureau.			
	<input type="checkbox"/>	have not been made; however, the time limit for making such amendments has NOT expired.			
	<input checked="" type="checkbox"/>	have not been made and will not be made.			
8.	<input type="checkbox"/>	A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).			
9.	<input type="checkbox"/>	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).			
10.	<input type="checkbox"/>	A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).			
Items 11. to 16. below concern other document(s) or information included:					
11.	<input checked="" type="checkbox"/>	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
12.	<input type="checkbox"/>	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
13.	<input checked="" type="checkbox"/>	A FIRST preliminary amendment.			
	<input type="checkbox"/>	A SECOND or SUBSEQUENT preliminary amendment.			
14.	<input type="checkbox"/>	A substitute specification.			
15.	<input type="checkbox"/>	A change of power of attorney and/or address letter.			
16.	<input checked="" type="checkbox"/>	Other items or information: Sequence Listing (27 pages)			

U.S. APPLICATION NO. <b>097700993</b> Unassigned		INTERNATIONAL APPLICATION NO. PCT/JP99/02644		ATTORNEY'S DOCKET NUMBER 081356/0154	
17. <input checked="" type="checkbox"/> The following fees are submitted: *				<b>CALCULATIONS</b>	
Basic National Fee (37 CFR 1.492(a)(1)-(5): Search Report has been prepared by the EPO or JPO.....\$860.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482).....\$690.00					
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) .....\$710.00					
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$1,000.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) .....\$100.00					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				\$860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 months from the earliest claimed priority date (37 CFR 1.492(e))					
Claims	Number Filed	Included in Basic Fee	Extra Claims	Rate	
Total Claims	15	-	20	= 0 x	\$18.00
Independent Claims	3	-	3	= 0 x	\$80.00
Multiple dependent claim(s) (if applicable)				\$270.00	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$860.00	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$0.00	
<b>SUBTOTAL =</b>				\$860.00	
Processing fee of \$130.00 for furnishing English translation later the 20 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	
<b>TOTAL NATIONAL FEE =</b>				\$860.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				+	
<b>TOTAL FEES ENCLOSED =</b>				\$860.00	
				Amount to be: refunded \$	
				charged \$	
a. <input checked="" type="checkbox"/> A check in the amount of \$860.00 to cover the above fees is enclosed.					
b. <input type="checkbox"/> Please charge my Deposit Account No. <u>19-0741</u> in the amount of \$0.00 to the above fees. A duplicate copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0741</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
Foley & Lardner Washington Harbour 3000 K Street, N.W., Suite 500 Washington, D.C. 20007-5109				SIGNATURE 	
				NAME STEPHEN A. BENT	
REGISTRATION NUMBER 29,768					

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Kazuo KOBAYASHI et al  
Title: ENDO- $\beta$ -N-ACETYLGLUCOSAMINIDASE GENE  
Appl. No.: Unassigned  
Filing Date: November 22, 2000  
Examiner: Unassigned  
Art Unit: Unassigned

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination of the present Application, Applicants respectfully request that the above-identified application be amended as follows:

**In the Claims:**

Please amend the following claims:

Claim 5, line 1, delete "any one of claims 2 to 4" and insert  
--Claim 2--.

Claim 7, line 1, delete "any one of claims 2 to 6" and insert  
--Claim 2--.

Please add the following new claims:

10. The gene according to claim 3, wherein the gene is derived from a microorganism belonging to the genus *Mucor*.
11. The gene according to claim 4, wherein the gene is derived from a microorganism belonging to the genus *Mucor*.
12. A recombinant vector which comprises the gene according to claim 3.

13. A recombinant vector which comprises the gene according to claim 4.
14. A recombinant vector which comprises the gene according to claim 5.
15. A recombinant vector which comprises the gene according to claim 6.

**REMARKS**

Applicants respectfully request that the foregoing amendments to Claims 5 and 7, and new Claims 10 through 15, be entered in order to avoid this application incurring a surcharge for the presence of one or more multiple dependent claims.

Respectfully submitted,

By 

Date November 22, 2000

FOLEY & LARDNER  
Washington Harbour  
3000 K Street, N.W., Suite 500  
Washington, D.C. 20007-5109  
Telephone: (202) 672-5404  
Facsimile: (202) 672-5399

Stephen A. Bent  
Attorney for Applicant  
Registration No. 29,768

## DESCRIPTION

Endo- $\beta$ -N-Acetylglucosaminidase Gene

## Technical Field

The present invention relates to a novel endo- $\beta$ -N-acetylglucosaminidase gene, and specifically relates to a gene where said gene is derived from the genus *Mucor*. Further, the present invention relates to a recombinant plasmid which comprises said gene, an organism transformed with said plasmid, and a method of producing a novel endo- $\beta$ -N-acetylglucosaminidase using said transformant.

## Background Art

Glycoproteins are widely found in animal tissue, plant tissue, and the cell membrane and cell wall etc. of eukaryotic microorganisms.

In recent years, it has become increasingly clear that the sugar chains of glycoproteins play an important role in mechanisms such as cell differentiation, carcinogenesis and intercellular recognition. In order to clarify these mechanisms, research into the correlation between sugar chain structure and its function is proceeding. As a means of achieving this objective, when cleaving a sugar chain from a glycoprotein or when identifying the structure of a sugar chain, various glycosidases are employed. Among these, endo- $\beta$ -N-acetylglucosaminidase acts on the asparagine-linked sugar chain (N-linked sugar chain, N-sugar chain) and has the action of cleaving the diacetyl-chitobiose portion that exists within the sugar chain thereby liberating the sugar chain.

Since endo- $\beta$ -N-acetylglucosaminidase can liberate the sugar portion of a glycoprotein from the protein portion, it is thought to be important in the analysis of the function and structure of sugar chains in glycoproteins.

Asparagine-linked sugar chains may be classified by their structure as high mannose type (mannane type sugar chain), hybrid type, or complex type.

Known endo- $\beta$ -N-acetylglucosaminidases include Endo H (A. L. Tarentino and F. Maley, *J. Biol. Chem.*, 249, 811 (1974)), Endo F (K. Takegawa, et al., *Eur. j. Biochem.*, 202, 175 (1991)), and EndoA (K. Takegawa, et al., *Appl. Environ. Microbiol.*, 55, 3107 (1989)). However, these enzymes only act upon sugars with specific structures, and do not act upon glycoproteins except in the presence of a denaturing agent.

Endo- $\beta$ -N-acetylglucosaminidase derived from *Mucor hiemalis* is capable of cleaving tri-antennary complex type sugar chains in respect of not only high mannose type (mannane type sugar chain) and hybrid type, but also complex type chains. Further, with the asialylated type, cleavage ability extends to tetra-antennary heteroglycan chains. Further, it is known that it is possible to free sugar chains from glycoproteins without subjecting the protein to denaturization treatment. (S. Kadowaki, et al., *Agric. Biol. Chem.*, 54, 97 (1990)). Therefore, endo- $\beta$ -N-acetylglucosaminidase derived from *Mucor hiemalis* can be said to be useful in the research of the functional and physiological role of sugar chains and proteins of glycoproteins.

On the other hand, conversion of mannane type sugar chains derived from yeast into sugar chains in a form compatible with humans, is extremely significant industrially. As methods for this conversion, *in vivo* conversion through improvement of the yeast sugar chain biosynthetic system by genetic manipulation, and *in vitro* conversion using the transglycosylation reaction can be considered. For the purpose of sugar conversion, endo- $\beta$ -N-acetylglucosaminidase is required to have as properties, 1) the substrate specificity, i.e an ability to cleave both mannane and complex types; and, 2) the ability to perform the transglycosylation reaction, which is the reverse reaction of the decomposition reaction. Therefore, endo- $\beta$ -N-acetylglucosaminidase derived from *Mucor hiemalis* can be said to be an appropriate enzyme for the practice of said conversion.

The present inventors, have proposed a sugar chain conversion technique using endo- $\beta$ -N-acetylglucosaminidase derived from *Mucor hiemalis* which can alter yeast sugar chains to human-compatible form. (Japanese Patent Application Laid-Open No: Hei 7-59587)

To perform sugar chain conversions such as the above, an authentic enzyme preparation of high purity is required in great amounts. In this case, improvement of enzyme productivity by conventional breeding methods using mold cells has been considered. However, since conventional breeding methods are limited predominantly to the method of selecting such an enzyme from mutant strains obtained using ultraviolet light or mutagens, the isolation of stable mutants is difficult. Further, conventional breeding methods are often accompanied by unfavorable transformations. Further, since molds generally produce protease enzymes, they are unfavorable for production of an enzyme for the purpose of sugar conversion. Since, in order to overcome these problems it is necessary to proceed through a number of purification steps, the work is complicated and the yield is low. For example, culturing a microorganism belonging to the genus *Mucor* which is a type of filamentous mold, even if purification of the supernatant of this culture is performed, contamination with protease cannot be prevented and preparation in large amounts is difficult because of low enzyme productivity of the microorganism, and thus this method was of little practical value.

Given the above, it is desired for the purpose of mass producing endo- $\beta$ -N-acetylglucosaminidase, that the gene for said enzyme be obtained and produced through the use of genetic engineering. Further, if the gene can be obtained, it can be expected that an enzyme with improved heat resistance and pH resistance and increased reaction rate can be obtained using protein engineering techniques. However, there have been no reported attempts at gene cloning to date.

#### Disclosure of Invention

It is an object of the present invention to provide an endo- $\beta$ -N-acetylglucosaminidase, an

endo- $\beta$ -N-acetylglucosaminidase gene, a recombinant vector which comprises said gene, an organism transformed with said vector, and a method of producing endo- $\beta$ -N-acetylglucosaminidase.

The present inventors, as a result of their intensive research directed to solving the above problem, based on partial amino acid sequence information of said endo- $\beta$ -N-acetylglucosaminidase derived from *Mucor hiemalis*, have succeeded in obtaining the gene that encodes said enzyme from a cDNA library prepared from *Mucor hiemalis* which is a bacteria which produces said enzyme, have further succeeded in expressing this gene in yeast, and thereby completed the present invention.

Thus, the present invention provides the recombinant protein of (a) or (b) below:

- (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 3; and,
- (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 3 by deletion, substitution, insertion, or addition of at least one amino acid and having the activity of endo- $\beta$ -N-acetylglucosaminidase.

Further, the present invention provides a endo- $\beta$ -N-acetylglucosaminidase gene which encodes the protein of (a) or (b) below, and a gene that hybridizes with said gene under stringent conditions, and which comprises DNA encoding a protein that has endo- $\beta$ -N-acetylglucosaminidase activity.

- (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 3; and,
- (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 3 by deletion, substitution, insertion, or addition of at least one amino acid and having the activity of endo- $\beta$ -N-acetylglucosaminidase.

Further, the present invention provides a gene comprising the DNA of (c) or (d) below:



- (c) a DNA consisting of the nucleotide sequence represented by SEQ ID NO: 2; and,  
(d) a DNA which hybridizes under stringent conditions with a DNA consisting of the nucleotide sequence represented by SEQ ID NO: 2, and encodes a protein having the activity of endo- $\beta$ -N-acetylglucosaminidase.

Said gene includes a gene derived from a microorganism belonging to the genus *Mucor*.

Further, the present invention provides a recombinant vector which comprises said gene.

Further, the present invention provides a transformant which comprises said recombinant vector.

Further, the present invention provides a method for producing an endo- $\beta$ -N-acetylglucosaminidase, comprising culturing said transformant, and collecting endo- $\beta$ -N-acetylglucosaminidase from the obtained culture product.

Below, the present invention will be described in detail.

The present invention is characterized by culturing endo- $\beta$ -N-acetylglucosaminidase producing microorganisms, purifying the endo- $\beta$ -N-acetylglucosaminidase from the obtained culture, designing degenerate probes from a partial amino acid sequence of said enzyme, cloning a gene encoding said enzyme by performing PCR, and further, cloning a gene encoding said enzyme from a cDNA library of the microorganism producing endo- $\beta$ -N-acetylglucosaminidase. Further, the present invention is characterized by obtaining a recombinant vector by introducing the cloned gene into a vector, as well as by obtaining a transformant by introducing said recombinant vector into a host cell. Further, the present invention is characterized by producing endo- $\beta$ -N-acetylglucosaminidase in large quantities by culturing said transformant.

#### 1. Culturing of endo- $\beta$ -N-acetylglucosaminidase producing microorganisms

Microorganisms for producing endo- $\beta$ -N-acetylglucosaminidase include microorganisms belonging to the genus *Mucor*, preferably *Mucor hiemalis*, and more preferably the *Mucor hiemalis* deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (1-1-3, Higashi, Tsukuba-shi, Ibaraki-ken, Japan) (Accession No. FERM BP-4991).

The medium composition used in culturing of these strains may be of any kind typically used in the culture of microorganisms.

Carbon sources include for example sugars such as glucose, sucrose, mannose, galactose, maltose, soluble starch and dextrin. Nitrogen sources include yeast extract, trypton, etc. As inorganic salts, apart from the inorganic salts contained in the above nitrogen sources, salts such as all varieties of sodium salts, potassium salts, calcium salts, magnesium salts and phosphate salts may be used. Vitamins may be added optionally.

The culture medium is sterilized by a conventional method, and the strain is inoculated into the medium. Thereafter, a shake culture, or aeration-agitation culture is performed at 20-30°C, pH 5-7 for 2 to 4 days.

In the present invention, culture is preferably performed at 25-30°C, pH 6, with galactose as the carbon source, yeast extract and trypton as the nitrogen sources, with concentrations of both carbon and nitrogen sources at 2-3% each, and the ratio of carbon source to nitrogen source at 2:3, for 3 to 4 days under good aeration conditions. Where the culture is performed under such conditions, the amount of enzyme produced is maximized, and in comparison to the known method (S. Kadowaki, et al., *Agric. Biol. Chem.*, 54, 97 (1990); glucose 0.5%, yeast extract 1%, peptone 1%), about 10-fold greater productivity can be achieved.

Further, in the present invention, to ensure the aeration conditions when culturing the microorganisms, use of a jar fermenter is preferable.

## 2. Purification of endo- $\beta$ -N-acetylglucosaminidase

The endo- $\beta$ -N-acetylglucosaminidase produced by the above bacterial strain is characterized by preservation of the following activity. In other words, it can be characterized by its activity to act on the asparagine-linked sugar chain in a glycoprotein, cleave the diacetyl-chitobiose portion within the sugar chain, and thereby liberate the sugar chain.

Purification of endo- $\beta$ -N-acetylglucosaminidase can be performed by the appropriate combination of known methods for separation and purification. Examples of such methods include methods using differences in solubility such as salt precipitation and solvent precipitation; methods using differences in molecular weight such as dialysis, ultrafiltration, gel filtration and SDS-polyacrylamide electrophoresis; methods using differences in electrostatic charge such as ion exchange chromatography; methods using differences in hydrophobicity such as hydrophobic chromatography and reverse phase chromatography, and methods using differences in isoelectric point such as isoelectric focusing.

In the present invention, by adopting a method of culturing which is an improvement over the above described known method (S. Kadowaki, et al., *Agric Biol. Chem.*, 54, 97 (1990)), and subjecting to many purification steps, endo- $\beta$ -N-acetylglucosaminidase can be efficiently purified, and it is possible to obtain a sufficient amount of the protein to determine the amino acid sequence necessary to obtain the gene. The obtained enzyme, as a result of purification and as a result of the analysis of the gene to be described below, consists of a single gene product with a molecular weight of approximately 85,000, and after post-translational partial digestion of the gene product, it was found to be composed of 2 or more subunits including peptides with molecular weights of approximately 60,000 and 14,000.

## 3. Cloning of the novel endo- $\beta$ -N-acetylglucosaminidase gene

It was clear that the endo- $\beta$ -N-acetylglucosaminidase obtained from *Mucor hiemalis* was

composed of at least 2 or more peptides.

Generally, when isolating a gene encoding a specific protein, a partial amino acid sequence of the protein is determined, and it is possible to isolate the desired gene from a gene library with a mixture of oligonucleotides consisting of degenerative codons as a probe. Further, after obtaining a fragment by PCR such as in the present invention, it is possible to isolate the desired gene from a gene library using this fragment as a probe.

However, since endo- $\beta$ -N-acetylglucosaminidase is a hetero-oligomeric molecule consisting of 2 or more subunits, there is the possibility that each subunit is encoded independently by their separate differing genes. Further, even if endo- $\beta$ -N-acetylglucosaminidase is derived from one gene, its structure, for example, the positional relationship between the regions encoding the two subunits within the structural gene was unclear.

Thus, the present inventors determined partial amino acid sequences for 2 subunits, and then after obtaining partial fragments by PCR, used said fragments as probes to achieve cDNA cloning and by analyzing the gene structure, clarified that the same gene coded for these 2 subunits. That is, it was clarified that the novel endo- $\beta$ -N-acetylglucosaminidase is produced as one polypeptide from the gene encoding this enzyme, and is processed by partial decomposition into 2 or more subunits.

The gene of the present invention is cloned by, for example, the following method.

#### (1) Cloning of the endo- $\beta$ -N-acetylglucosaminidase gene

In the present invention, an example of a DNA fragment comprising a gene encoding a novel endo- $\beta$ -N-acetylglucosaminidase is the DNA fragment indicated by the restriction enzyme map shown in Fig. 2. This fragment can be isolated using genetic engineering methods from a cDNA library with an mRNA template prepared from a microorganism belonging to the genus *Mucor*, preferably from a strain of *Mucor hiemalis*, and more preferably from the strain of *Mucor hiemalis* deposited under accession number FERM BP-4991 at the National

Institute of Bioscience and Human-Technology, (See the method described in, for example, *Molecular Cloning: A Laboratory Manual* (Sambrook, Maniatis et al, Cold Spring Harbour Laboratory Press (1989))

Preparation of mRNA can be performed according to a typical method. For example, after culturing the mRNA source, *Mucor hiemalis*, total RNA is obtained from the cultured cell with a kit available on the market (ISOGEN (Nippon Gene Company)), and then purified with a purification kit available on the market (mRNA Purification Kit (Pharmacia Biotech)). In the preparation of mRNA, it is preferable to keep the culturing time short to control the decomposition of mRNA.

With the thus obtained mRNA as a template, a single-strand cDNA is synthesized using an oligo dT primer and a reverse transcriptase enzyme. Thereupon, a duplex cDNA is synthesized from said single stranded cDNA. A recombinant vector is then constructed by incorporating the duplex cDNA into a suitable cloning vector. A cDNA library can be obtained by transforming *E.coli* using the obtained recombinant vector, and selecting transformants using tetracycline resistance and ampicillin resistance as an indicator.

Here, transformation of *E.coli* is performed according to a method such as the Hanahan method [Hanahan, D. : *J. Mol. Biol.* 166 : 557-580 (1983)]. When a plasmid is to be used as a vector, it is necessary to include a gene for resistance to a drug such as tetracycline or ampicillin. Further, a cloning vector other than a plasmid, for example,  $\lambda$  phage or the like can be used.

A strain having the desired DNA is selected (screened) from the thus obtained transformant. Screening methods include, for example, a method of synthesizing sense and antisense primers corresponding to a partial amino acid sequence of endo- $\beta$ -N-acetylglucosaminidase, and using this to perform a polymerase chain reaction (PCR). Template DNA may include for example, genomic DNA or cDNA synthesized by reverse transcription from the above-mentioned mRNA. As primers, in respect of the sense chain, for example, 5'-

CARTTRCARCCNGAYGAYAA-3' (SEQ ID NO: 5) synthesized on the basis of amino acid sequence: PSLQLQPDDK (SEQ ID NO: 4) and 5'-CCHACNGAYCARAAAYATYAA-3' (SEQ ID NO: 7) synthesized on the basis of amino acid sequence: SYRNPEIYPTDQNIK (SEQ ID NO: 6), may be used. Further, in respect of the antisense chain 3'-GGDTGNCTRGTYTTTRIARTT-5' (SEQ ID NO: 8) synthesized on the basis of amino acid sequence: SYRNPEIYPTDQNIK (SEQ ID NO: 6) and 3'-TTYCCDGTYGCDAAARTTRGT-5' (SEQ ID NO: 10) synthesized on the basis of amino acid sequence: GQRFNHRESHDVETEI (SEQ ID NO: 9), may be used. However, the present invention is not limited to these primers.

Thus, the obtained DNA amplification fragment is labeled with for example <sup>32</sup>P, <sup>35</sup>S or biotin and taken as a probe, and is then made to hybridize with the cDNA library of the transformant, which library has been denatured and immobilized onto a nitrocellulose filter. Screening can then be performed by searching the obtained positive strains.

## (2) Determination of the nucleotide sequence

Determination of the nucleotide sequence of the obtained clone is performed. Determination of the nucleotide sequence may be performed by known methods such as the Maxam-Gilbert chemical modification method or dideoxy method, though typically determination of the sequence is performed using an automated nucleotide sequencer. (For example, PERKIN-ELMER 377A DNA Sequencer)

The full length sequence of the endo- $\beta$ -N-acetylglucosaminidase gene is indicated by SEQ ID NO: 1. Therein, a preferable example of the gene of the present invention, is the nucleotide sequence from position 71 to position 2305 (SEQ ID NO: 2) of the nucleotide sequence indicated by SEQ ID NO: 1. Further, the gene of the present invention includes not only a sequence which encodes the amino acid sequence represented by SEQ ID NO: 3 or the below described amino acid sequence having an equivalent sequence, but also encompasses degenerate isomers encoding identical polypeptides which differ in respect of degenerate codons only.

A nucleotide sequence encoding an amino acid sequence having an equivalent sequence can be prepared using a method such as site-directed mutagenesis. That is, mutations may be introduced by known methods such as the Kunkel method or Gapped duplex method, or other methods equivalent thereto, using for example a mutation introduction kit that employs site-directed mutagenesis (e.g. Mutant-K (Takara), Mutant-G (Takara)) etc., or using Takara's LA PCR *in vitro* Mutagenesis series kit.

Further, an endo- $\beta$ -N-acetylglucosaminidase gene includes not only DNA consisting of the nucleotide sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2, but also a DNA which hybridizes under stringent conditions with said DNA, and encodes a protein having the activity of endo- $\beta$ -N-acetylglucosaminidase. Stringent conditions refer to, for example, the conditions of a sodium concentration of 50-300mM, preferably 150mM and a temperature of 50-68°C, preferably 65°C.

Once the nucleotide sequence of the endo- $\beta$ -N-acetylglucosaminidase gene (SEQ ID NO: 1) is identified, since the nucleotide sequence of the DNA fragment having the sequence from position 71 to 2305 of the said nucleotide sequence (open reading frame) is determined (SEQ ID NO: 2), it is possible to obtain the endo- $\beta$ -N-acetylglucosaminidase gene by chemical synthesis; by PCR with genomic DNA as a template and the 5' and 3' terminal sequences of the open reading frame (SEQ ID NO: 2) (e.g. 5'-ATGCCTTCACTTCAATTGCAACC-3' (SEQ ID NO: 11) and 5'-CTAGTTTAATGACAAATCTATGC-3' (SEQ ID NO: 12) as primers; or, by hybridization with a DNA fragment having the nucleotide sequence of an endo- $\beta$ -N-acetylglucosaminidase gene as a probe.

The plasmid pZL-Endo (See Example 3 below) which comprises the gene of the present invention was introduced into *E.coli* DH10B (Title: DHBpZL-Endo) and deposited at National Institute of Bioscience and Human-Technology (1-1-3, Higashi, Tsukuba-shi, Ibaraki-ken, Japan) on April 28, 1998 under accession number FERM BP-6335.

In the present invention, the amino acid sequence represented by SEQ ID NO: 3 or a polypeptide comprising an equivalent sequence, is provided as a preferable example of a recombinant novel endo- $\beta$ -N-acetylglucosaminidase. Here, "equivalent sequence" refers to a sequence which comprises the amino acid sequence represented by SEQ ID NO: 3 and in which at least one amino acid is inserted, substituted, deleted or added to either end, and which retains said novel endo- $\beta$ -N-acetylglucosaminidase activity. Retention of novel endo- $\beta$ -N-acetylglucosaminidase activity in this equivalent sequence means that the sequence maintains activity sufficient for it to be used in an almost identical manner under identical conditions to the polypeptide having the full sequence represented by SEQ ID NO: 3 in actual forms of use which exploit this activity. It is clear that it is possible for a person skilled in the art to select and produce with no particular difficulty such an equivalent sequence, referring to the sequence represented by SEQ ID NO: 3. For example, within the amino acid sequence represented by SEQ ID NO: 3, at least 1, preferably 1 to 10, more preferably 1 to 5 amino acids may be deleted; at least 1, preferably 1 to 10, more preferably 1 to 5 amino acids may be added or inserted; or, at least 1, preferably 1 to 10, more preferably 1 to 5 amino acids may be substituted. Accordingly, the protein of the present invention includes a polypeptide having the amino acid sequence from position 2 to 744 of the amino acid sequence represented by SEQ ID NO: 3 in the Sequence Listing (one in which the methionine at position 1 of the amino acid sequence represented by SEQ ID NO: 3 has been deleted.)

Here, through the partial amino acid sequence analysis of the present invention and gene structure analysis, it became clear that 2 or more natural type subunits were produced by cleavage of a precursor polypeptide on the C terminal side of at least the histidine at position 510 and the asparagine at position 627 in the amino acid sequence represented by SEQ ID NO: 3.

## 2. Construction of a recombinant vector and transformant

The present invention provides a DNA molecule comprising the gene of the present invention, in particular, an expression vector. This DNA molecule can be obtained by incorporating a DNA fragment encoding the novel endo- $\beta$ -N-acetylglucosaminidase according to the present invention into a vector molecule. Accordingly, if transformation of a host cell is performed



with a DNA molecule, particularly in the form of an expression vector, which includes a DNA fragment encoding the novel endo- $\beta$ -N-acetylglucosaminidase of the present invention in a form such that it is replicable within the host cell and the said gene is expressible, it is possible to cause production of the novel endo- $\beta$ -N-acetylglucosaminidase of the present invention in the host cell.

The DNA molecule according to this invention can be constructed based on the method described in the above-referenced *Molecular Cloning: A Laboratory Manual* (*supra*).

#### (1) Construction of a recombinant vector

The vector to be used in the present invention may be appropriately selected from a virus, plasmid, cosmid vector or the like in consideration of the type of host cell to be used.

For example, where the host cell is *E.coli*, bacteriophages of the  $\lambda$  phage line, plasmids of the pBR line (pBR322, pBR325 etc.) and pUC line (pUC118, pUC119 etc); where the host cell is *Bacillus subtilis*, plasmids of the pUB line (pUB110 etc); and where the host cell is yeast, vectors of the YEp and YCp lines (e.g. YEp13, YEp24, YCp50 etc.), or pG-3-Not used in the Examples below, may be used. Further, animal viruses such as a retrovirus or vaccinia virus, or insect virus vectors such baculovirus can be used.

To introduce the gene of the present invention into the vector, methods for ligating the gene to the vector such as first cleaving the purified DNA with a suitable restriction enzyme, and then inserting the gene at suitable restriction sites or multicloning sites of the vector DNA, are employed.

It is necessary that the gene of the present invention be incorporated into the vector such that the function of this gene is exhibited. Thus, it is preferable that the vector of the present invention includes a selective marker. Drug-resistant markers and auxotrophic markers can be used as selective markers.

Further, it is preferable that the DNA molecule to be used as the expression vector of the present invention has DNA sequences necessary for the expression of the novel endo- $\beta$ -N-acetylglucosaminidase gene such as transcription regulating signals and translation regulating signals such as, for example, a promoter, transcription initiation signal, ribosome binding site, translation stop signal and a transcription termination signal.

## (2) Construction of the transformant

The transformant of the present invention can be obtained by introducing the recombinant vector of the present invention into a host in a manner allowing expression of the subject gene. There is no particular limitation on the host that may be used as long as it allows expression of the gene of the present invention. Examples include bacteria of the genus *Escherichia* such as *Escherichia coli*, of the genus *Bacillus* such as *Bacillus subtilis*, or of the genus *Pseudomonas* such as *Pseudomonas putida* etc., and yeasts such as *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Candida boidinii* and *Pichia pastoris*.

As host cells, apart from *E.coli*, *B. subtilis*, and yeast, animal cells such as COS cells and CHO cells etc., and insect cells such as Sf9 and Sf21 etc. may be used.

Where a bacterium such as *E.coli* is used as a host, the recombinant vector of the present invention preferably is autonomously replicable within the bacterium and comprises a promoter, ribosome binding site, the gene of the present invention, and a transcriptional termination sequence. A gene which controls the promoter may also be included.

Examples of *E. coli* include *Escherichia coli* K12, DH1, DH5  $\alpha$ , JM109 etc. Examples of *Bacillus subtilis* include *Bacillus subtilis* MI 114, 207-21 etc. It is known that there exist strains of *Bacillus subtilis* that secrete proteins out of the microorganism body. There are also known strains that secrete hardly any protease. The use of such strains as hosts is preferable.

As a promoter, a promoter within the inserted fragment that is able to function even in the

host, may of course be used. Examples of promoters in *E.coli* include lactose operon (lac) and tryptophan operon (trp), etc.

As a method for introducing the recombinant vector into bacteria, any method for introducing DNA into bacteria may be employed and there is no particular limitation thereon. Examples include a method using calcium ions [Cohen, S.N. et al.: *Proc. Natl. Acad. Sci.*, USA, 69:2110-2114(1972)], and electroporation.

Where yeast is to be the host, *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Candida utilis*, etc., may be used. In this case, there is no particular limitation on the promoter that may be used as long as it can express in yeast. For example, promoters such as alcohol dehydrogenase (ADH), acidic phosphatase (PHO), galactose gene (GAL), and glyceraldehyde-3-phosphate dehydrogenase gene (GAPDH) promoters, heat shock protein promoter, MF  $\alpha$  1 promoter, PGK promoter, GAP promoter and AOX1 promoter may preferably be used.

As a method for introducing the recombinant vector into yeast, any method for introducing DNA into yeast may be employed and there is no particular limitation thereon. Examples include electroporation [Becker, D.M. et al.: *Methods. Enzymol.*, 194: 182-187 (1990)], spheroplast method [Hinnen, A. et al.: *Proc. Natl. Acad. Sci.*, USA, 75: 1929-1933 (1978)], and lithium acetate method [Itoh, H. : *J. Bacteriol.*, 153:163-168 (1983)].

Where an animal cell is to be the host, monkey cell COS-7, Vero, Chinese hamster ovary cell (CHO cell), mouse L cell, rat GH3 and human FL cell, etc. may be used. As a promoter, SR  $\alpha$  promoter, SV40 promoter, LTR promoter, CMV promoter or the like can be used. Also, the initial promoter of human cytomegalovirus or the like may be used.

Examples of a method for introducing the recombinant vector into an animal cell include electroporation, calcium phosphate method and lipofection method.

Where an insect cell is to be the host, Sf9 cell, Sf21 cell and the like may be used.

Examples of a method for introducing the recombinant vector into an insect cell include calcium phosphate method, lipofection, and electroporation.

#### 4. Production of the protein of the present invention

A protein of the present invention has an amino acid sequence encoded by a gene of the present invention, or has said amino acid sequence into which said modification of at least 1 amino acid has been introduced, and has the activity of endo- $\beta$ -N-acetylglucosaminidase.

The protein of the present invention can be obtained by culturing the above-mentioned transformant and collecting the protein from this culture product. "Culture product" refers to either the culture supernatant, the cultured cells or microbial cells, or disrupted cells or microbial cells.

Either a natural medium or synthetic medium may be used as a medium for culturing transformants obtained with microorganisms such as *E. coli* or yeast as hosts, as long as it contains a carbon source, a nitrogen source, inorganic salts and the like, which are able to be assimilated by the microorganism and it may be used to efficiently perform a culture of the transformant.

As carbon sources, carbohydrates such as glucose, fructose, sucrose and starch, organic acids such as acetic acid and propionic acid, and alcohols such as ethanol and propanol are used.

As nitrogen sources, inorganic acids such as ammonia, ammonium chloride, ammonium sulfate, ammonium phosphate, organic acids such as ammonium acetate, or other nitrogen containing compounds, as well as peptone, meat extract, corn steep liquor or the like are used.

As inorganic matter, potassium (I) phosphate, potassium (II) phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, iron (I) sulfate, manganese sulfate, copper

sulfate and calcium carbonate, etc are used.

Culturing is typically performed under aerobic conditions such as a shake culture or aeration-agitation culture, at 37°C at 12 to 72 hours. During culturing, pH is maintained at 4-7.5. Regulation of pH is performed using inorganic or organic acid or alkali solutions and the like.

During culturing, antibiotics such as ampicillin and tetracycline may be added to the medium as required.

When the microorganism transformed with an expression vector containing an inducible promoter is cultured, an inducer may be added to the culture as required. For example, when culturing a microorganism transformed with an expression vector which uses a Lac promoter, isopropyl- $\beta$ -D-thiogalactoside (IPTG) and the like may be added to the culture, and when culturing a microorganism transformed with an expression vector using a trp promoter, indole acetic acid (IAA) may be added.

As culture media for culturing a transformant obtained from an animal host cell, the generally used RPMI1640 medium, DMEM medium or these medium to which fetal calf serum and the like have been added, are used.

Culturing is typically performed over 2 to 10 days at 37°C in the presence of 5% CO<sub>2</sub>. Antibiotics such as kanamycin and penicillin and the like may be added during culturing as required.

After culturing, when the protein of the present invention has been produced within the microorganisms or cells, the protein of the present invention is extracted by disrupting the microorganisms or cells. When the protein of the present invention has been produced outside the microorganisms or cells, the culture fluid may be used as is, or the microorganisms or cells removed by centrifugal isolation, etc.

Purification of the recombinant novel endo- $\beta$ -N-acetylglucosaminidase, is performed by the suitable combination of known separation and purification methods. Examples of such methods include methods using differences in solubility such as salt precipitation, and solvent precipitation methods; methods using differences in molecular weight such as dialysis, ultrafiltration, gel filtration and SDS-polyacryl electrophoresis; methods using differences in electrostatic charge (valence) such as ion exchange chromatography; methods using differences in hydrophobicity such as hydrophobic chromatography and reverse phase chromatography; and, methods using differences in isoelectric point such as isoelectric focusing.

In the present invention, as indicated in the Examples below, when this gene was made to express under the control of GAPDH promoter, in a *Saccharomyces cerevisiae* host, high enzyme activity was confirmed within the cell extract. This indicated that it was possible to produce active novel endo- $\beta$ -N-acetylglucosaminidase in large quantities through the expression of the gene of the present invention in the recombinant.

#### Brief Description of Drawings

Figure 1 is an electrophoresis photograph indicating results for purified endo- $\beta$ -N-acetylglucosaminidase.

Figure 2 is a restriction enzyme map of pZL-Endo which comprises the full length sequence of a novel endo- $\beta$ -N-acetylglucosaminidase gene.

Figure 3 indicates the entire nucleotide sequence of the fragment inserted at the Sal I-Not I sites of pZL-Endo which comprises the full length sequence of a novel endo- $\beta$ -N-acetylglucosaminidase gene.

Figure 4 indicates the entire nucleotide sequence of the fragment inserted at the Sal I-Not I sites of pZL-Endo which comprises the full length sequence of a novel endo- $\beta$ -N-acetylglucosaminidase gene. (Continuation of Figure 3)

Figure 5 shows the deduced amino acid sequence from novel endo- $\beta$ -N-acetylglucosaminidase gene and the nucleotide sequence of a DNA encoding said amino acid

sequence.

Figure 6 shows the deduced amino acid sequence from novel endo-  $\beta$  -N-acetylglucosaminidase gene and the nucleotide sequence of a DNA encoding said amino acid sequence. (Continuation of Figure 5)

Figure 7 shows the deduced amino acid sequence from novel endo-  $\beta$  -N-acetylglucosaminidase gene and the nucleotide sequence of a DNA encoding said amino acid sequence. (Continuation of Figure 6)

Figure 8 shows the structure of expression vector pGEndo-SC ,which comprises a novel endo-  $\beta$  -N-acetylglucosaminidase gene for use in *Saccharomyces cerevisiae*.

Figure 9 is a chromatography photograph which indicates the expression of novel endo-  $\beta$  -N-acetylglucosaminidase in yeast into which said enzyme gene has been introduced.

#### Best Mode for Carrying Out the Invention

Below, the present invention will be described more specifically using examples. It is contemplated, however, that the technical scope of the present invention is not to be limited to these examples. Unless otherwise indicated herein the procedures were performed in accordance with the methods as are described in *Molecular Cloning: A Laboratory Manual* (Sambrook, Maniatis et al, Cold Spring Harbour Laboratory Press (1989)).

#### Example 1: Measurement of Enzyme Activity

Measurement of the activity of endo-  $\beta$  -N-acetylglucosaminidase was performed fundamentally in accordance with the method indicated in S. Kadowaki, et al., *Agric. Biol. Chem.*, 54, 97 (1990). That is, the reaction was performed using dansylated human asialo-transferrin glycopeptide (DNS-GP) as a substrate in a potassium phosphate buffer (pH6.0) at 37°C and activity measured by thin layer chromatography (TLC) or by HPLC under the following conditions.

Analysis conditions for TLC:

Development phase: HPTLC silica gel 60 (Merck)

Solvent: butanol: acetic acid: water = 2:1:1

Detection: detection by fluorescence method

Analysis conditions for HPLC:

Column: TSK-gel ODS80TM (TOSO)

Solvent: 25mM sodium borate buffer (pH 7.5) +11% acetonitrile

Column temperature: 50°C

Flow rate: 0.5ml/minute

Detector: fluorescence detector

Activity was defined such that 1 unit is equivalent to the amount of enzyme required to produce 1  $\mu$ mol of dansylated asparagyl acetylglucosamine in one minute under the above described HPLC measurement conditions.

#### Example 2: Culturing *Mucor hiemalis*

A medium (galactose 2%, yeast extract 3%) 100ml was placed in a 500ml Sakaguchi flask, and inoculated with a third to a fifth of a slant of *Mucor hiemalis* spore, and culture was performed at 28°C for 2 days. The microbial cells separated from the culture by suction filtration were used in the preparation of mRNA.

Regarding preparation of the enzyme, the above culture, following cultivation, was transferred to 2 liter of the medium in a 3 liter jar fermenter, and culturing was performed for four days under conditions of 28°C, rotation speed of 300-400rpm, and aeration volume of 2 liters per minute.

#### Example 3: Purification of novel endo- $\beta$ -N-acetylglucosaminidase

Four liters of the culture (from two batches of cultures performed in 3-liter jar fermenter) obtained in Example 2 was subjected to suction filtration to separate the cells, and concentrated to 200ml using ultrafiltration. This crude enzyme solution was subjected to ion exchange chromatography (Pharmacia Q Sepharose FF, 500ml) equilibrated with 10mM



potassium phosphate buffer containing 5mM EDTA. The column was washed with the same buffer solution followed by elution of endo- $\beta$ -N-acetylglucosaminidase with a linear gradient of 900ml 0M-0.3M NaCl. Reagents were added to the active fraction such that the final concentrations of 1M ammonium sulfate, 50mM potassium phosphate containing 5mM EDTA were attained. The product was subjected to hydrophobic chromatography (TOSO Phenyl-TOYOPEARL 650S 200ml) equilibrated with the same buffer. The column was washed with this same buffer and then endo- $\beta$ -N-acetylglucosaminidase was eluted with a linear gradient of 1M-0M ammonium sulfate containing 1mM EDTA(600ml).

The obtained eluate was concentrated to 5ml with ultrafiltration membrane (molecular weight cut-off 13000) then washed and desalted with 10mM potassium phosphate buffer containing 1mM EDTA and 0.15M NaCl (pH7.0). Next, the active fraction was applied to a gel filtration chromatography column (Pharmacia Sephacryl S300) equilibrated with the same buffer solution, and endo- $\beta$ -N-acetylglucosaminidase was eluted with the same buffer solution.

The active fraction was concentrated with ultrafiltration membrane (molecular weight cut-off 13000) then washed and desalted with 10mM potassium phosphate containing 1mM EDTA (pH7.0). Next, the active fraction was subjected to hydroxy apatite chromatography (TOSO TSK-gel HA1000) equilibrated with the same buffer. The column was washed with this same buffer and then endo- $\beta$ -N-acetylglucosaminidase was eluted with a linear gradient of 0M-0.3M ammonium sulfate containing 1mM of EDTA (pH7.0)(30ml).

The active fraction was concentrated with ultrafiltration membrane (molecular weight cut-off 13000) then washed and desalted with a 25mM bis-tris buffer solution adjusted to pH 7.1 with iminodiacetic acid. The active fraction was subjected to isoelectric point chromatography (Pharmacia, MonoP) with equilibrated with the same buffer solution. The column was washed with this same buffer and then endo- $\beta$ -N-acetylglucosaminidase was eluted with 50ml of 10% Polybuffer 74 (Pharmacia) adjusted to pH 3.9 with iminodiacetic acid.

The active fraction was concentrated with ultrafiltration membrane (molecular weight cut-off

13000) then washed and desalted with 10mM potassium phosphate buffer containing 1mM EDTA (pH7.0). Next, the active fraction was subjected to ion exchange chromatography (Pharmacia, MonoQ). The column was washed with this same buffer and then endo- $\beta$ -N-acetylglucosaminidase was eluted with a linear gradient of 0M-0.3M NaCl (30ml).

The active fraction was concentrated with ultrafiltration membrane (molecular weight cut-off 13000) then washed and desalted with 50mM potassium phosphate buffer containing 1mM EDTA (pH7.0), to obtain an enzyme sample. It should be noted that each column chromatography was performed using FPLC (Pharmacia).

The mass of the protein was measured using Protein Assay Kit manufactured by BioRad, or by absorbance (280nm). The molecular weight and isoelectric point of the protein was measured by SDS-PAGE (15-25% gradient), gel filtration chromatography, IEF-PAGE and the like.

From the activity of each of the fractions in two-dimensional electrophoresis by Native-SDSPAGE and IEF-SDSPAGE, and in the above chromatography, and from the results of SDS-PAGE analysis, bands of at least 60kDa (denoted p60) and 14kDa (denoted p14) on SDS-PAGE were detected (Fig. 1).

**Example 4: Determination of a partial amino acid sequence of novel endo- $\beta$ -N-acetylglucosaminidase**

Partial amino acid sequence analysis was performed according to the Iwamatsu method (Seikagaku (Biochemistry) 63, 139-143 (1991)). The purified enzyme was suspended in an electrophoresis buffer solution (10% glycerol, 2.5% SDS, 2% 2-mercaptoethanol, 62mM Tris HCl buffer (pH6.8)), and was subjected to SDS polyacrylamide electrophoresis. After electrophoresis, said enzyme was transferred from the gel to 10cm by 7cm PVDF membrane ((ProBlot) Applied Biosystems) by electroblotting. Using ZARUTO Blot Type IIs (Zarutorius) as an electroblotting device, electroblotting was preformed at 160mA for 1 hour.

After transfer, the portion of the membrane onto which the said enzyme was transferred was cut out and part of this portion was directly analyzed with a gas phase protein sequencer whereby the N-terminal amino acid sequence was determined. Further, the remaining membrane was soaked in 300  $\mu$ l of a reducing buffer solution (8M guanidine-HCl, 0.5M Tris-HCl buffer (pH8.5), 0.3% EDTA, 2% acetonitrile), 1mg of dithiothreitol (DTT) was added, and reduction was performed for about 1 hour at 25°C in the presence of argon. To this, 3.0mg of moniodoacetic acid dissolved in 10  $\mu$ l of 0.5N sodium hydroxide solution was added and was stirred for 20 minutes under darkened conditions. PVDF membrane was taken out, and after thorough enough washing with 2% acetonitrile, it was soaked in 100mM acetic acid containing 0.5% polyvinylpyrrolidone-40, and allowed to stand for 30 minutes. Afterward, the PVDF membrane was washed thoroughly with water. A 1mm square was cut from the membrane and soaked with a digestion buffer (8% acetonitrile, 90mM Tris-HCl buffer pH 9.0) and 1 pmol of *Acromobacter* protease I (Wako Pure Chemicals Industries) was added thereto. The enzyme was then digested for 15 hours at room temperature. The digestion product was separated by reversed phase high performance liquid chromatography on C18 column (Wakosil AR II C18 300Å 2.0 x 150mm(Wako Pure Chemicals Industries)), and seven peptide fragments were obtained in respect of each subunit.

As elution solvents for the peptides, solvent A (0.05% trifluoroacetic acid) and solvent B (2-propanol/acetonitrile solution 7:3, containing 0.02% trifluoroacetic acid) were used, and the elution was performed for 40 minutes with a linear concentration gradient from 2 to 50% of solvent B, at a rate of 0.25mL/min.

Amino acid sequences of fragmented peptides obtained from the novel endo- $\beta$ -N-acetylglucosaminidase candidate protein were analyzed. Fragments derived from p60 and fragments derived from p14, were denoted as p60-AP and p14-AP, respectively. Sequencing of the obtained fragmented peptides was carried out using a gas phase protein sequencer PPSO-10 (Shimadzu) by the Edman degradation method in accordance with the manual.

The obtained partial amino acid sequences are indicated in Table 1.

Table 1 – Partial amino acid sequence of endo-  $\beta$  -N-acetylglucosaminidase candidate protein

p60		
p60-AP-5	PSLQLQPDDK	(SEQ ID NO:
17)		
p60-AP-6	(K) SYRNPEIYPtDQNIK	(SEQ ID NO: 18)
p60-AP-8	(K) FNVSSVALQPRVK	(SEQ ID NO: 19)
p60-AP-9	(K) MDRLFLCGgK	(SEQ ID NO:
20)		
	S	
p60-AP-11	(K) GQRFNHRESHDVETEI	(SEQ ID NO:
21)		
	mal p lllt	
p14		
p14-AP-1	(K) EGYISSSGSIDLSLN	(SEQ ID NO: 22)

In the amino acid sequence described in Table 1, amino acids indicated by lower case letters of the alphabet are undetermined amino acids within the amino acid sequence.

Since *Acromobacter* protease I, used on the partial amino acid sequence, specifically cleaves on the carboxyl side of a lysine residue, K (lysine) has been written in brackets on the N-terminus side of the sequences below.

Since the p60-AP-5 was found to be the N-terminus amino acid sequence, K (Lysinse) in brackets was removed.

In respect of the *Acromobacter* protease I digestion products of p60 and p14, molecular

weight analysis was also performed with on-line mass analyzer (PE Sciex API-III), combined with reverse phase high performance liquid chromatography (Hitachi L6200) on C-18 column (GL Science Inertsil ODS-3 0.5 x 40mm). The results of analysis are shown in Table 2.

Table 2 Results of /Lys-C digest product on the 60kDa peptide (p60) and the 14kDa peptide (p14) by LC/MS analysis

p60	Measured Value	Ideal Value	Error Margin	Corresponding Sequence	SEQ ID NO:
AP-1:	950.50	950.47	+0.03	(K)NIQGNYYK	23
AP-2:	1160.50	1160.56	-0.06	(K)YSDYPPPPPK	24
AP-3:	733.25	733.41	-0.16	(K)LSLDASK	25
AP-4:	1838.50	1837.91	+0.59	(K)SYRNPEIYPTDQNIK	18
AP-5:	1141.00	1140.59	+0.41	( )PSLQLQPD DK.....p60 N-terminus	17
	1157.50	1156.75	+0.75	(K)NTDGIFLNYWWK	26
AP-6:	1774.75	1774.94	-0.19	(K)GB'SLRYIYRTLLMK	27
AP-7:	701.50	701.39	+0.11	(K)LTVAB'H .....p60 C-terminus	28
	1544.50	1543.79	+0.71	(K)PQLLLTHDMAGGYK	29
	1621.00	1620.73	+0.27	(K)SMNELRDWTPDEK	30
AP-8:	1444.75	1444.83	-0.08	(K)FNVSSVALQPRVK	19
AP-9:	945.75	945.58	+0.17	(K)LAPVSFALK	31
	2655.00	2655.33	-0.33	(K)GQRFNHRESHDVETEISPLYK	32
AP-10:	2206.75	2206.11	+0.64	(K)ITSSSLDB'DHGAFLLGGTSLIK	33
AP-11:	2335.00	2335.16	-0.16	(K)NELFFKNTDGIFLNYWWK	34
p14	Measured Value	Ideal Value	Error Margin	Corresponding Sequence	SEQ ID NO:
AP-1:	888.75	888.45	+0.30	(K)IVIEAVNK	35
AP-2:	1392.50	1392.76	-0.26	( )SSRIQDLFWK.....p14 N-terminus	36
AP-3:	1541.50	1541.73	-0.23	(K)EGYISSSGSIDLSLN..p14 C-terminus	22
	1608.50	1608.84	-0.34	(K)TDSSRIQDLFWK	37

\* B represents cysteine, carboxymethyl.

In Table 2, the fragment having a measured value of 701.50 in respect of mass (M+H<sup>+</sup>) is p60-AP-7, and the fragment having a measured value of 1541.50 is nearly identical to the molecular weight of p14-AP-3, and it was found that the amino acid at this C-terminus was not K (lysine). Regarding the fragments digested with *Acromobacter* protease I, since, due to the substrate specificity of this enzyme, fragments other than C-terminus fragment of the subunit itself, will have a C-terminus amino acid residue that is lysine (K), it is clear that these fragmented peptides were the C-terminus fragments of the subunits p60 and p14.

A homology search on the determined p60 and p14 partial amino acid sequences using the protein database BLASTP indicated that the obtained sequences were novel. From the above results, gene cloning of p60 and p14 was performed selecting the p60 and p14 as endo- $\beta$ -N-acetylglucosaminidase candidates.

#### Example 5: Construction of a *Mucor hiemalis* strain cDNA library.

Firstly, total RNA was extracted from 5g of the microorganisms obtained in Example 2 using ISOGEN (Nippon Gene, Inc.). From the extracted total RNA, mRNA was purified using an mRNA Purification Kit (Pharmacia Biotech). cDNA was synthesized from the mRNA using a SuperScript™ Lambda System for cDNA Synthesis and  $\lambda$  Cloning Kit (GIBCO BRL), and then ligated to a Sal I adapter, and finally linked (or ligated) to  $\lambda$  ZipLox™Sal I-Not I Arms (GIBCO BRL). Packaging was performed using Gigapack III Gold Packaging Extract (Stratagene), for infection of *E.coli* Y1090 strain thereby constructing the cDNA library.

#### Example 6: Cloning of novel endo- $\beta$ -N-acetylglucosaminidase cDNA.

PCR primers were designed based on the partial amino acid sequences p60-AP-5, p60-AP-6, p60-AP-11. These sequences are indicated below. The symbols used herein are all based on IUPAC-IUB.

p60-AP-5

p60-AP-5F 5' CARTTRCARCCNGAYGAYAA 3' (sense primer) (SEQ ID NO: 5)

p60-AP-6

p60-AP-6F 5' CCHACNGAYCARAAYATYAA 3' (sense primer) (SEQ ID NO: 7)

p60-AP-6R 3' GGDGTGCTRGTYTTRTARTT 5' (antisense primer) (SEQ ID NO: 8)

p60-AP-11

p60-AP-11R 3' TTYCCDGTGCDAAARTTRGT 5' (antisense primer) (SEQ ID NO: 10)

Genomic DNA was purified from *Mucor hiemalis* culture mass by the phenol method and when genomic PCR (30 seconds at 94°C, 1 minute at 55°C, 1 minute at 72°C, 30 cycles) was performed, specific amplified bands were confirmed. Regarding p60, with a combination of p60-AP-5F and p60-AP-11R primers, a PCR fragment of 1.7kb, with combination of p60-AP-5F and p60-AP-6R, a PCR fragment of 1.5kb, and with a combination of p60-AP-6F and p60-AP-11R primers, a PCR fragment of 0.2kb was obtained. Regarding this fragment, subcloning into pCR-Script Amp was performed using a pCR-Script cloning kit (Stratagene). It was predicted from analysis by restriction enzyme digestion, that the amplification fragment of p60-AP-5F and p60-AP-11R included the amplification fragments of p60-AP-5F and p60-AP-6R, and p60-AP-6F and p60-AP-11R. Thus, the nucleotide sequence of the amplification fragment of p60-AP-5F and p60-AP-11R was determined using PRISM Ready Reaction kit (Applied Biosystems) and PRISM 3 7 7 DNA sequencer (Applied Biosystems). Gene analysis was performed using DNASIS (Hitachi Software Engineering Co., Ltd.) etc.

As a result, the amplification fragment of p60-AP-5F and p60-AP-11R included the determined other partial amino acid sequence. Therefore, it was determined that this fragment was a part of the p60 gene. Thus, new DNA primers were constructed based on the inside sequence of the PCR amplification fragment, and RT-PCR was then performed (under the same conditions as genomic PCR), using Access RT-PCR System (Promega) and with the mRNA obtained in Example 5 as a template. The sequences of the newly constructed DNA primers are as follows:

p60-AP-5NF 5' CACTTAAGTCTATGAATGAG 3' (sense primer) (SEQ ID NO: 13)  
 p60-AP-6NR 3' CGATAGCTTTAGGTCTCTAA 5' (antisense primer) (SEQ ID NO: 14)

As a result, a fragment of approximately 1.2kb was amplified. Upon sequencing the amplified fragment it was found that a fragment not including introns had been obtained. Therefore, cDNA cloning was performed using this fragment as a probe. Labeling was performed with  $\alpha$ -<sup>32</sup>P dCTP (110TBq/mmol) using Megaprime DNA labeling systems (Amersham).

The full-length gene was obtained from the cDNA library, obtained in Example 5, by plaque hybridization. As a result, 5 positive clones were obtained from 200,000 plaques. Of these, 4 clones were subjected to secondary screening thereby obtaining a single plaque. Further, *E.coli* DH10B was infected with phage fluid obtained from the plaque, and a plasmid derived from pZL1 was recovered from the phage. Restriction enzyme analysis was performed in respect of these clones, and nucleotide sequence analysis of the clone comprising the longest upstream region was performed. This plasmid was named pZL-Endo. (Fig. 2)

The nucleotide sequence of the inserted Sal I-Not I fragment of about 2.3kb was determined. In other words, the restricted fragments were subcloned into pBluescript II KS+ (Stratagene) or pUC118 (Takara Shuzo), and by producing a continuous deletion mutant using exonuclease III and mung bean nuclease, a plasmid having a variety of deletion mutations was constructed, and the sequence of a Sal I-Not I fragment consisting of 2370bp was determined using a DNA sequencer. (Figs. 3-4, SEQ ID NO: 1)

Analysis of the predicted region of the structural gene was performed and it was found that there existed an open reading frame encoding an amino acid sequence consisting from 744 amino acid residues (deduced molecular weight 85kDa, Figs 5-7, SEQ ID NO: 2), and this amino acid sequence comprised all of the determined partial amino acid sequences of p60 and p14. Since the amino acid next to p60-AP-5 on the N-terminus side was not lysine but methionine, it was confirmed that ATG encoding this methionine was the start codon for translation. It had therefore been clarified that the N-terminus of the enzyme of the present invention was proline.

On the other hand, as with the result of qualitative analysis, it was found that p14-AP-3 was the C-terminus of the protein encoded by the gene of the present invention. Further, together with the results of mass analysis, it was predicted that at least one type of p14 N-terminus was serine, the amino acid at position 628 in the amino acid sequence indicated in SEQ ID NO: 2.

From the above, it was clear that the 5' region of the gene of the present invention encodes



p60, and the 3' region encodes p14. Since the N-terminal signal sequence could not be found in the amino acid sequence, the enzyme of the present invention is thought to be an intracellular protein. However, since there exists a plurality of bands in Figure 1, the enzyme of the present invention is thought to be affected by action of a protease due to the lysis of the cell.

#### Example 7: Construction of the endo- $\beta$ -N-acetylglucosaminidase gene expression vector

In this Example, an expression vector for *Saccharomyces cerevisiae*, complementary to a TRP1 gene, including an endo- $\beta$ -N-acetylglucosaminidase gene and a GAPDH gene promoter-PGK terminator was constructed.

To obtain the open reading frame encoding the 744 amino acids confirmed in Example 3, DNA primers based on DNA sequences equivalent to the amino acid sequences of the N-terminus and C-terminus to which a Not I site had been added at both termini, were synthesized and PCR was performed with pZL-Endo as a template thereby obtaining an amplified fragment. The following are the sequences of the sense and antisense primers:

Endo-Not-F (sense primer)

5' GGGGCGGCCGCTTTTATTTTACATAAATATGCCTTCACTTC 3' (SEQ ID NO:

15)

Endo-Not-R (antisense primer)

5' CCCGCGGCCGCTAGTTTAATGACAAATCTATGCTACC 3' (SEQ ID NO: 16)

After separation by agarose gel electrophoresis, the amplified fragment was recovered and purified using Prep-A-Gene DNA Purification System (Bio-Rad). Further, after digestion of this fragment with Not I, it was purified and inserted into the Not I of pBluescript II KS+ thereby producing pBlue-Endo-Not.

Since the novel endo- $\beta$ -N-acetylglucosaminidase gene is the gene derived from mold, it was thought that expression in yeast was suitable. An expression plasmid for *Saccharomyces*

*cerevisiae* with trp1 gene as a selective marker, said trp 1 gene comprising a *Saccharomyces cerevisiae* glyceraldehyde-3-phosphate dehydrogenase gene (GAPDH) promoter, a 3-phosphoglycerate kinase (PGK) gene terminator, and a tryptophan synthesis gene TRP1 gene, was constructed with expression vector pG-3 (Methods in Enzymology Vol. 194 p. 389). Said pG-3-Not was constructed by digesting pG-3 with BamHI, blunt-ending by Klenow processing followed by addition of a Not I linker.

The above-mentioned pBlue-Endo-Not was digested with Not I and an insertion fragment of approximately 2.3kb separated and purified by agarose gel electrophoresis. This fragment was inserted at the Not I site of pG-3-Not thereby constructing pGEndo-SC. (Fig. 8)

Example 8: Expression of novel endo-  $\beta$  -N-acetylglucosaminidase in *Saccharomyces cerevisiae*.

A pep4 gene disrupted strain of the yeast *Saccharomyces cerevisiae* YPH500 strain (Stratagene) was used as a host. A pep4 gene disrupted strain was produced by the method of Sikorski, R.S. and Hieter, P (Genetics Vol. 122 19-27 (1989)). The said strain was transformed with 10  $\mu$ g of pGEndo-SC. Transformation was performed by the lithium acetate method (see WO95/32289) and transformants were selected on a culture plate not including tryptophan (yeast nitrogen base 0.67%, casamino acid 0.5%, glucose 1%).

Confirmation of the activity of intracellular novel endo-  $\beta$  -N-acetylglucosaminidase was performed in respect of the transformants. For the transformed cells cultured for 2 days at 30°C in a 5mL YPD medium (yeast extract 1%, polypeptone 2%, glucose 2%), centrifugation was performed at 1500g for 5 minutes at 4°C, thereby separating the supernatant and the cell mass. The cell mass was washed with distilled water. Ten microliters of a mixture of 50mM potassium sulfate buffer (pH 6.0) and 5mM EDTA was added to the cell mass and suspended well. Further, 50mg of glass beads was added and after vigorous stirring, centrifuged, and the supernatant taken was as the cell extract.

Measurement of activity was performed by TLC or HPLC using DNS-GP as a substrate. Results with TLC are indicated in Figure 9. As with the sample reacted with the enzyme purified from the supernatant of the *Mucor hiemalis* culture, a peak identical with the dansylated asparagyl acetylglucosamine (DNS-Asn-GlcNAc) was obtained from the pGEndo-SC product. On the other hand, no peak corresponding to DNS-Asn-GlcNAc was detected from the culture supernatant of the negative control strain transformed with pG-3-Not. The pGEndo-SC cell extract was concentrated by a factor of ten, desalted, reacted with DNS-GP and the peak corresponding to DNS-Asn-GlcNAc was fractionated using HPLC under the above-mentioned conditions. The fractionated samples were concentrated with an evaporator, and mass spectrometry analysis was performed thereon. As a result, it was confirmed that the mass spectrometry results matched with the DNS-Asn-GlcNAc results. Thus it was apparent that the gene product encoded by the pGEndo-SC insertion fragment was a novel endo- $\beta$ -N-acetylglucosaminidase.

Table 3 indicates the activity (product amount) per liter of the culture of the novel endo- $\beta$ -N-acetylglucosaminidase of this invention. This activity was 48 times the value for *Mucor hiemalis*.

TABLE 3 Novel endo- $\beta$ -N-acetylglucosaminidase activity

	Activity (Unit/Liter)
<i>M. hiemalis</i> culture supernatant	0.9
Culture fluid of <i>S. cerevisiae</i> into which novel endo- $\beta$ -N-acetylglucosaminidase gene was introduced*	43.2

\*After cell collection from the culture, the cells were disrupted with glass beads. After separation of the supernatant using a centrifuge, the activity of the supernatant was measured, and the activity per culture volume was calculated from this value.

This specification incorporates the content described in the specification and/or the drawings of Japanese Patent Application No. 10-141717 which is the application upon which priority for the present application is based.

All publications, patents and patent applications cited herein are incorporated herein by reference in their entirety.

### Industrial Applicability

The present invention provides an endo- $\beta$ -N-acetylglucosaminidase, an endo- $\beta$ -N-acetylglucosaminidase gene, a recombinant plasmid which comprises said gene, an organism transformed with said plasmid, and a method of producing endo- $\beta$ -N-acetylglucosaminidase.

By introducing a vector which comprises the gene of the present invention into a host, and causing the gene to be expressed, endo- $\beta$ -N-acetylglucosaminidase can be produced efficiently and in large quantities.

The enzyme of the present invention is an industrially important enzyme in the analysis and assay of sugar chains and the modification of sugar chains. The transformants obtained by the present invention produce the subject enzyme in large quantities and make a large contribution to industries that employ these enzymes.

### Free Text of Sequence Listing

SEQ ID NO: 4: A partial amino acid sequence of endo- $\beta$ -N-acetylglucosaminidase

SEQ ID NO: 5: An oligonucleotide designed from a partial amino acid sequence of endo- $\beta$ -N-acetylglucosaminidase

SEQ ID NO: n indicates a, g, c, or t (Location: 12)

SEQ ID NO: 6: A partial amino acid sequence of endo- $\beta$ -N-acetylglucosaminidase

SEQ ID NO: 7: An oligonucleotide designed from a partial amino acid sequence of endo- $\beta$ -N-acetylglucosaminidase

SEQ ID NO: 7: n indicates a, g, c, or t (Location: 6)

SEQ ID NO: 8: An oligonucleotide designed from a partial amino acid sequence of endo- $\beta$ -N-acetylglucosaminidase

SEQ ID NO: 8: n indicates a, g, c, or t (Location: 15)

SEQ ID NO: 9: A partial amino acid sequence of endo- $\beta$ -N-acetylglucosaminidase

SEQ ID NO: 10: An oligonucleotide designed from a partial amino acid sequence of endo- $\beta$ -N-acetylglucosaminidase

SEQ ID NO: 11: An oligonucleotide sequence of the 5' terminal region of an endo- $\beta$ -N-acetylglucosaminidase gene

SEQ ID NO: 12: An oligonucleotide sequence of the 3' terminal region of an endo- $\beta$ -N-acetylglucosaminidase gene

SEQ ID NO: 13: An oligonucleotide designed from the nucleotide sequence of an endo- $\beta$ -N-acetylglucosaminidase gene

SEQ ID NO: 14: An oligonucleotide designed from the nucleotide sequence of an endo- $\beta$ -N-acetylglucosaminidase gene

SEQ ID NO: 15: An oligonucleotide designed from the nucleotide sequence of an endo- $\beta$ -N-acetylglucosaminidase gene

SEQ ID NO: 16: An oligonucleotide designed from the nucleotide sequence of an endo- $\beta$ -N-acetylglucosaminidase gene

SEQ ID NO: 20: Xaa indicates Met or Ser (Location: 2)

SEQ ID NO: 21: Xaa indicates Gly or Met (Location: 2)

SEQ ID NO: 21: Xaa indicates Gln or Ala (Location: 3)

SEQ ID NO: 21: Xaa indicates Arg or Leu (Location: 4)

SEQ ID NO: 21: Xaa indicates Asn or Pro (Location: 6)

SEQ ID NO: 21: Xaa indicates Arg or Leu (Location: 8)

SEQ ID NO: 21: Xaa indicates Glu or Leu (Location: 9)

SEQ ID NO: 21: Xaa indicates Ser or Leu (Location: 10)

SEQ ID NO: 21: Xaa indicates His or Thr (Location: 11)

SEQ ID NO: 27: carboxymethylcystein (Location: 3)

SEQ ID NO: 28: carboxymethylcystein (Location: 6)

SEQ ID NO: 33: carboxymethylcystein (Location: 8)

## CLAIMS

1. A recombinant protein selected from the group consisting of:
  - (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 3;  
and,
  - (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 3 by deletion, substitution, insertion, or addition of at least one amino acid and having the activity of endo- $\beta$ -N-acetylglucosaminidase.
2. An endo- $\beta$ -N-acetylglucosaminidase gene encoding:
  - (a) a protein having the amino acid sequence represented by SEQ ID NO: 3; or,
  - (b) a protein having an amino acid sequence represented by SEQ ID NO: 3 by deletion, substitution, insertion, or addition of at least one amino acid and having the activity of endo- $\beta$ -N-acetylglucosaminidase.
3. A gene comprising the following DNA:
  - (c) a DNA consisting of a nucleotide sequence represented by SEQ ID NO: 2; or,
  - (d) a DNA which hybridizes under stringent conditions with a DNA consisting of a nucleotide sequence represented by SEQ ID NO: 2, and which encodes a protein having endo- $\beta$ -N-acetylglucosaminidase activity.
4. A gene which hybridizes under stringent conditions with the gene according to claim 2, and which comprises DNA encoding a protein having endo- $\beta$ -N-acetylglucosaminidase activity.
5. The gene according to any one of claims 2 to 4, wherein the gene is derived from a microorganism belonging to the genus *Mucor*.
6. The gene according to claim 5, wherein the microorganism belonging to the genus *Mucor* is *Mucor hiemalis*.
7. A recombinant vector which comprises the gene according to any one of claims 2 to 6.
8. A transformant which comprises the recombinant vector of claim 7.
9. A method of producing endo- $\beta$ -N-acetylglucosaminidase comprising culturing the transformant according to claim 8 and collecting endo- $\beta$ -N-acetylglucosaminidase from

the culture product.

**FEDERAL BUREAU OF INVESTIGATION**

FIG. 1




Purification Result for Endo-  $\beta$  -N-acetylglucosaminidase (15-25% gradient SDS-PAGE)

Lane 1: Purified endo-  $\beta$  -N-acetylglucosaminidase from *Mucor hiemalis*

Lane 2: Molecular weight markers



FIG. 2



Restriction enzyme map for pZL-Endo including the full-length novel endo- $\beta$ -N-acetylglucosaminidase gene.

## FIG. 3

```

10      20      30      40      50      60
GTGACCCAC GGTCCCGG ACGCTGGGC GGACGCGTG GCGGACCGT GGGTTTATT

70      80      90      100     110     120
TTACATAAAT ATGCTTCAC TTCAATTGCA ACCTGATGAC AAACAGACAC CTGTTTCTTT

130     140     150     160     170     180
TGCACTERAG TCTATGAATG AGTTGAAGGA CTGGACGCCA GACGAAAAGA TAAAGTTTAA

190     200     210     220     230     240
CGTTCTAAGC GTGGCACTAC AGCCTCGTGT GAAAAACGCC CTGAACCTC AATTATGTGT

250     260     270     280     290     300
AACTCATGAT ATGGCAGGAG GATATAAAGA AGATAAAAT ATTCAAGGAA ACAATTATAA

310     320     330     340     350     360
AGACATTATAT AACATTCAAT ATTGGCATT TTGCTATATT TCTCTCATGA

370     380     390     400     410     420
GCGAGTTAGC ATTCTCCAG TCAATTGGAC AAATGCTTGT CATAGAAATG GTGTAAAGTG

430     440     450     460     470     480
TTTAGGTAAT TTTTATAGTAG AAGGAAATTA CCNAATGCAT GAAATGGAAG CCTTGTCTCA

490     500     510     520     530     540
CGGTCCACCT TTAATTAAAT ACACGTACGA CCTATGAGA TTATGAGATC GGTATATATC

550     560     570     580     590     600
AGACCAATTA GTTGTCTATTG CTAACACTTA TGGTTTGTAT GGCTGGTTGT TCAATATTTA

610     620     630     640     650     660
ATGCAATTC TTTCCTTTTC CTACAAATCC AAAAATCAAA GCTGAAGAGT TGGCAAGATT

670     680     690     700     710     720
TCDACATAT TTTAAGGAAA AATTGCATAA CGAAATACCT GGATCTCAAC TCATTTGGTA

730     740     750     760     770     780
CGACAGCATG ACAATTAAGG GAGAAATCCA CTGGCAGAAC CAGCTCACAT GGAATAATGA

790     800     810     820     830     840
GTATATTTTT AAAAAACAGG ATGGTATTTT TTGAAATTAT TGGTGGAAAA AAGAAATACC

850     860     870     880     890     900
TGAATGCGCG COTAGAGTAG CTGAAGGAAT AGGTAGATCA GGTTAGAAG TTTATTTTGG

910     920     930     940     950     960
TACAGATGTA TGGGAAGGC ATACTTATGG TGGCGGTGGT TTCAATTCAT ATAAGGGTGT

970     980     990     1000
AAAACTGCC TACTCTGCAA TGACATCTTC TGCATTATTT GGTATGGCAT GGACATACGA

1030    1040    1050    1060    1070    1080
GCATTTCGAA AAGTCTGAAT TTGAAAGAT GGAATGTTTG TTTGGTGTG GTGGTAATA

1090    1100    1110    1120    1130    1140
CTCTGACTAT CTTCCCGCAC CTCTTAATAA CCCAGATGAC GAAAAAGAG TAGAAGCGCA

1150    1160    1170    1180    1190    1200
TGATAGTGAA GATGAGCTCA TGTAACGACA CAAGAAAGGT ATTGCTGACA CGGTAGAAATC

1210    1220    1230    1240    1250    1260
TATTCCTGTA CCAGGACAGC ATTGGTTTGT TACCAATTTT GATAGGGGGT TTGGAAATAG

1270    1280    1290    1300    1310    1320
GTTTATATAT AGAGGAAGA GATTACTTTC TCAGCCTTGG TCCCATTTAT CGCATCAAGC

1330    1340    1350    1360    1370    1380
TATTCCTCCC AATAAAAGCT ATCGAAATCC AGAGATTAT CCACATGATC AAAACATTAA

```

Entire nucleotide sequence of the fragment inserted into the Sal I-Not I sites of pZL-Endo including the full-length novel endo- $\beta$ -N-acetylglucosaminidase gene.

FIG. 4

1390	1400	1410	1420	1430	1440
AATCACATAGT	TCTCTCGATT	GCAGTCATGG	AGCTTTTCTTT	GGTGGAACTT	CGCTTATATT
1450	1460	1470	1480	1490	1500
CAAAGGCCAA	CGTTTCAATC	ATAGAGAAATC	GCATGATGTT	GAAACTGAAA	TTAGTATACC
1510	1520	1530	1540	1550	1560
TCTGTATTAAG	CTTTCATTAG	ATGCTAGTAA	AGGATGCTCA	TTGCGTTATA	TTTATAGAAC
1570	1580	1590	1600	1610	1620
TTTGTGTGATG	AAAGATGTAA	AGTTGACAGT	AGCATGTGAC	TTTTTCGTTAA	AAACAACGA
1630	1640	1650	1660	1670	1680
CTCAGTTAAT	TTCTTCAAGG	TATGGCAGCC	AGATGAAAA	TTCTCTTTTG	AATATGATGA
1690	1700	1710	1720	1730	1740
TGGAATGAGA	GCCACTGTTA	CAACTGAAAA	TTCTACCGAA	AGCAGATGCT	TTTTATTAGC
1750	1760	1770	1780	1790	1800
TACAACAGAA	GAAGATACAG	GAGAAAAATGA	TTGGATAACA	AAAACATATTA	ATGTGCGCTCG
1810	1820	1830	1840	1850	1860
TGTTCCAGAA	GGAAGTCAAT	TATACATTAC	AAGACTTGAA	GTGAGCGTAG	TATTAGATAC
1870	1880	1890	1900	1910	1920
AGCTGGTTTA	GTAGGTCTTG	TTAATCAAGT	TATTGCTTGC	TTGGGATATA	TTAGCATCAT
1930	1940	1950	1960	1970	1980
ACCAACTATA	AATCTCGGAA	TAAAAACAGA	TTTCATCACGC	ATTATTCAGG	ATCTCTTTTG
1990	2000	2010	2020	2030	2040
GAAAGATCAG	AAATATACCA	AAATCGGAAA	AGAAAGTTTA	GACGACATAG	CTCAAGAAGA
2050	2060	2070	2080	2090	2100
AGTTTATAGA	TATTATGGAA	CATTGAACITG	GGAAAAACACA	GCAAAATGTAG	TAAACGCTTG
2110	2120	2130	2140	2150	2160
GGAGGAAATA	GATTACTACA	ACGTTTTTTTA	CAAGAAAAGT	GACGACTCTG	CAACTCGCAT
2170	2180	2190	2200	2210	2220
CTTTTITAGGA	ACAGCATTCT	GTAATCAATT	TCGTGTATCT	GGTTTAGATA	TTATTITATC
2230	2240	2250	2260	2270	2280
TAAGCTACCA	AAGATAGTTA	TTGAAGCTGT	TAACAAAGAA	GGATACATCT	CTTCAAGTGG
2290	2300	2310	2320	2330	2340
TAGCATATGAT	TTGTTCATTAA	ACTAGGACTT	GAAATAAATAT	ATTATGATAA	AGAAAAAATA
2350	2360	2370	2380	2390	2400
AAAAAAAAAA	AAAAAAAAAG	GCGGCGCC.	.....	.....	.....

Entire nucleotide sequence of the fragment inserted into the Sal I-Not I sites of pZL-Endo including the full-length novel endo- $\beta$ -N-acetylglucosaminidase gene. (Continued)

FIG. 5

5'	ATG	OCT	TCA	CTT	CAA	TTG	CAA	OCT	GAT	GAC	AAA	CTA	GCA	OCT	GTT	TCT	TTT	GCA	9	18	27	36	45	54
	M	P	S	L	Q	L	Q	P	D	D	K	L	A	P	V	S	F	A						
	CTT	AAG	TCT	ATG	AAT	GAG	TTG	AGG	GAC	TGG	ACG	CCA	GAC	GAA	AAG	ATA	AAG	TTT	63	72	81	90	99	108
	L	K	S	M	N	E	L	R	D	W	T	P	D	E	K	I	K	F						
	AAC	GTT	TCA	AGC	GTG	GCA	CTA	CAG	OCT	CGT	GTG	AAA	AAC	GCC	CTG	AAA	OCT	CAA	117	126	135	144	153	162
	N	V	S	S	V	A	L	Q	P	R	V	K	N	A	L	K	P	Q						
	TTA	TTG	TTA	ACT	CAT	GAT	ATG	GCA	GGA	GAT	AAA	GAA	GAT	AAA	AAT	ATT	CAA	171	180	189	198	207	216	
	L	L	L	T	H	D	M	A	G	G	Y	K	E	D	K	N	I	Q						
	GGA	AAC	AAT	TAT	AAA	GAC	ATT	TAT	AAC	ATT	CAA	TAT	TGG	CAT	TTA	GCT	GAT	ACT	225	234	243	252	261	270
	G	N	N	Y	K	D	I	Y	N	I	Q	Y	W	H	L	A	D	T						
	TTT	GTA	TAT	TTC	TCT	CAT	GAG	GGA	GTT	AGC	ATT	OCT	CCA	GTC	AAT	TGG	ACA	AAT	279	288	297	306	315	324
	F	V	Y	F	S	H	E	R	V	S	I	P	P	V	N	W	T	N						
	GCT	TGT	CAT	AGA	AAT	GGT	GTA	AAG	TGT	TTA	GGT	CAT	TTT	TTA	GTA	GAA	GGA	AAT	333	342	351	360	369	378
	A	C	H	R	N	G	V	K	C	L	G	T	F	L	V	E	G	N						
	AAC	CAA	ATG	CAT	GAA	ATG	GAA	GCC	TTC	CAC	GGT	CCA	OCT	TTA	CTT	AAT	AAC	387	396	405	414	423	432	
	N	Q	M	H	E	M	E	A	L	L	H	G	P	P	L	L	N	N						
	ACT	GAC	GAC	OCT	ATG	AGA	TTA	TGG	AGT	CCG	TAT	TAT	GCA	GAC	CAA	TTA	GTT	GCT	441	450	459	468	477	486
	T	D	D	P	M	R	L	W	S	P	Y	Y	A	D	Q	L	V	A						
	ATT	GCT	AAA	CAC	TAT	GGT	TTT	GAT	GGC	TGG	TTG	TTC	AAT	ATT	GAA	TGC	GAA	TTC	495	504	513	522	531	540
	I	A	K	H	Y	G	F	D	G	W	L	F	N	I	E	C	E	F						
	TTT	OCT	TTT	OCT	ACA	AAT	CCA	AAA	TTC	AAA	GCT	GAA	GAG	TTG	GCA	AAG	TTT	CTA	549	558	567	576	585	594
	F	P	F	P	T	N	P	K	F	K	A	E	E	L	A	X	F	L						
	CAC	TAT	TTT	ATG	GAA	AAA	TTG	CAT	AAC	GAA	ATA	OCT	GGA	TCT	CAA	CTC	ATT	TGG	603	612	621	630	639	648
	H	Y	F	K	E	K	L	H	N	E	I	P	G	S	Q	L	I	W						
	TAC	GAC	AGC	ATG	ACA	AAT	GAA	GGA	GAA	ATC	CAC	TGG	CAG	AAC	CTC	ACA	TGG	657	666	675	684	693	702	
	Y	D	S	M	T	N	E	G	E	I	H	W	O	N	O	L	T	W						

Amino acid sequence deduced from the novel Endo- $\beta$ -N-acetylglucosaminidase gene, and the nucleotide sequence of the DNA encoding this amino acid sequence.

FIG. 6

711	720	729	738	747	756
AAA AAT GAG TTA TTT	TTT TTT AAA AAC ACG	GAT GGT ATT TTT	TTG AAT TAT TGG	TOG	
K N E L F F K N T D G I F L N Y W W					
765	774	783	792	801	810
AAA AAA GAA TAC CCT	GAA ATG GCG CGT	AGA GTA GCT GAA	GGA ATA GGT	AGA TCA	
K K E Y P E M A R R V A E G I G R S					
819	828	837	846	855	864
GGT TTA GAA GTT TAT	TTT GGT ACA GAT	GTA TGG GGA AGG	CAT ACT TAT	GGT GGC	
G L E V Y F G T D V W G R H T Y G G					
873	882	891	900	909	918
GGT GGT TTC AAA TCA TAT	AAG GGT GTA AAA ACT	GCC TAC TCT GCA	ATG ACA TCT		
G G F K S Y K G V K T A Y S A M T S					
927	936	945	954	963	972
TCT GCA TTA TTT GGT	ATG GCA TGG ACA TAC	GAG CAT TTC GAA AAG	TCT GAA TTT		
S A L F G M A W T Y E H F E K S E F					
981	990	999	1008	1017	1026
GAA AAG ATG GAT CGT	TTG TTT TGG TGT GGT	GGT AAA TAC TCT	GAC TAT CCT	CCC	
E K M D R L F W C G G K Y S D Y P P					
1035	1044	1053	1062	1071	1080
CCA CCT CCT AAA AAC	CCA GAT GAC GAA AAA	GAA GTA GAA AGC	GAT GAT AGT	GAA	
P P P K N P D D E K E V E S D D S E					
1089	1098	1107	1116	1125	1134
GAT GAG CTC ATG TRC	GGA CAC AAG AAA GGT	ATT GCT GAC ACG	GTA GAA TCT	ATT	
D E L M Y G H K K G I A D T V E S I					
1143	1152	1161	1170	1179	1188
CCT GTA CCA GGA ACA	GAT TGG TTT GTT ACC	AAT TTT GAT AGG	GGG TTT GGA	AAT	
P V P G T D W F V T N F D R G F G N					
1197	1206	1215	1224	1233	1242
AGG TTT TAT TAT AGA	GGA AAG AGA TTA CTT	TCT CAG CCT TGG	TCC CAT TTA	TCG	
R F Y Y R G K R L L S Q P W S H L S					
1251	1260	1269	1278	1287	1296
CAT CAA GCT ATT CTC	CCC AAT AAA AGC TAT	CGA AAT CCA GAG	ATT TAT CCC	ACT	
H Q A I L P N K S Y R N P E I Y P T					
1305	1314	1323	1332	1341	1350
GAT CAA AAC ATT AAA	ATC ACT AGT CTC	GAT TGC GAT CAT	GGA GCT TTT	CIT	
D Q N I K I T S S L D C D H G A F L					
1359	1368	1377	1386	1395	1404
GGT GGA ACC TCG CTT	ATT ATC AAA GGC	CAA CGT TTC AAT	CAT AGA GAA	TCG	CAT
G G T S L I I K G Q R F N H R E S H					
1413	1422	1431	1440	1449	1458
GAT GTT GAA ACT	GAA ATT AGT ATA	CCT CTG TAT AAG	CIT TCA TTA	GAT GCT	AGT
D V E T E I S I P L Y K L S L D A S					


Amino acid sequence deduced from the novel Endo- $\beta$ -N-acetylglucosaminidase gene, and the nucleotide sequence of the DNA encoding this amino acid sequence. (Continued)

FIG. 7

1467	1476	1485	1494	1503	1512
AAA GGA TCA	TTC CGT TAT	AGA ACT TTG	TTG ATG AAA	GAT GTA AAG	
K G C S L	R Y I Y R	T L L M K	D V K		
1521	1530	1539	1548	1557	1566
TTG ACA GTA	GCA TGT CAC	TTT TCG TTA	AAA ACA AAC	GAC TCA GTT	AAT TTC TTC
L T V A C	H P S L K	T N D S V	N F F		
1575	1584	1593	1602	1611	1620
AAG GTA TGG	CAG CCA GAT	GAA AAT TTC	TCT TTT GAA	TAT GAT GAT	GGA ATG ACA
K V W Q P	D E N F S	F E Y D D	G M R		
1629	1638	1647	1656	1665	1674
GCC ACT GTT	ACA ACT GAA	AAT TCT ACC	GAA AGC AGA	TGC TTT TTA	TTA CGT ACA
A T V T T	E N S T E	S R C F L	L R T		
1683	1692	1701	1710	1719	1728
ACA GAA GAA	GAT ACA GAA	AAT GAT TGG	ATA ACA AAA	GAT AAT AAT	GTG CCT
T E E D T	G E N D W	I T K T I	N V P		
1737	1746	1755	1764	1773	1782
GCT GTT CCA	GAA GGA AGT	CAA TTA TAC	ATT ACA CTT	GAA GTG AGC	GTA GTA
A V P E G	S Q L Y I	T R L E V	S V V		
1791	1800	1809	1818	1827	1836
TTA GAT ACA	GCT GGT TTA	GTA GGT CTT	GTT AAT CAA	GTT ATT GCT	TGC TTG GGA
L D T A G	L V G L V	N Q V I A	C L G		
1845	1854	1863	1872	1881	1890
TAT ATT AGC	ATC ATA CCA	ACT ATA AAT	TCT GGA ATA	AAA GAT TCA	TCA CAC
Y I S I I	P T I N S	G I K T D	S S R		
1899	1908	1917	1926	1935	1944
ATT ATT CAG	GAT CTC TTT	TGG AAA GAT	CAG AAA TAT	ACC AAA ATC	GGA AAA GAA
I I Q D L	F W K D Q	K Y T K I	G K E		
1953	1962	1971	1980	1989	1998
AGT TTA GAC	ATA OCT CAA	GAA GAA GTT	CAT AGA TAT	TAT TAT GGA	ACA TTG AAC
S L D D I	A Q E E V	H R Y Y G	T L N		
2007	2016	2025	2034	2043	2052
TGG GAA AAC	ACA GCA AAT	GTA GTA AAC	GCT TGG GAG	GAA ATA GAT	TAC TAC AAC
W E N T A	N V V N A	W E E I D	Y Y N		
2061	2070	2079	2088	2097	2106
GTT TTT TAC	AAA GAA AGT	GAC GAC TCT	GCA ACT CCG	ATC TTT TTA	GGA ACA GCA
V F Y K E	S D D S A	T R I F L	G T A		
2115	2124	2133	2142	2151	2160
TTC TGT AAT	CAA TTT CGT	GTA TCT GGT	TTA GAT ATT	ATT TTA TCT	AAG CTA CCA
F C N Q F	R V S G L	D I I L S	K L P		
2169	2178	2187	2196	2205	2214
AAG ATA GTT	ATT GAA GCT	GTT AAC AAA	GAA GGA TAC	TAT TCT TCA	AGT GGT AGC
K I V I E	A V N K E	G Y I S S	S G S		
2223	2232				
ATA GAT TTG	TCA TTA AAC	TAG 3'			
I D L S L	N *				


Amino acid sequence deduced from the novel Endo- $\beta$ -N-acetylglucosaminidase gene, and the nucleotide sequence of the DNA encoding this amino acid sequence. (Continued)

FIG. 8



Structure of expression vector pGEndo-SC for the use in *Saccharomyces cerevisiae*, which comprises a novel endo- $\beta$ -N-acetylglucosaminidase gene.

FIG. 9



Expression of endo- $\beta$ -N-acetylglucosaminidase enzyme in yeast into which an endo- $\beta$ -N-acetylglucosaminidase gene has been introduced.

- Lanes 1-3: Cellular extract of *S. cerevisiae* YPH500 (pep4) into which an endo- $\beta$ -N-acetylglucosaminidase gene has been introduced.
- Lane 4: Purified endo- $\beta$ -N-acetylglucosaminidase derived from *M. hiemalis*
- Lane 5: Cellular extract of *S. cerevisiae* YPH500 (pep4)



DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I HEREBY DECLARE:

THAT my residence, post office address, and citizenship are as stated below next to my name;

THAT I believe I am the original, first, and sole inventor (if only one inventor is named below) or an original, first, and joint inventor (if plural inventors are named below or in an attached Declaration) of the subject matter which is claimed and for which a patent is sought on the invention entitled

ENDO- $\beta$ -N-ACETYLGLUCOSAMINIDASE GENE

(Attorney Docket No. 081356/0154)

the specification of which (check one)

☐ is attached hereto.

☒ was filed on May 20, 1999 as United States Application Number or PCT International Application Number PCT/JP99/02644 and was amended on \_\_\_\_\_ (if applicable).

THAT I do not know and do not believe that the same invention was ever known or used by others in the United States of America, or was patented or described in any printed publication in any country, before I (we) invented it;

THAT I do not know and do not believe that the same invention was patented or described in any printed publication in any country, or in public use or on sale in the United States of America, for more than one year prior to the filing date of this United States application;

THAT I do not know and do not believe that the same invention was first patented or made the subject of an inventor's certificate that issued in any country foreign to the United States of America before the filing date of this United States application if the foreign application was filed by me (us), or by my (our) legal representatives or assigns, more than twelve months (six months for design patents) prior to the filing date of this United States application;

THAT I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment specifically referred to above;

THAT I believe that the above-identified specification contains a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention, and sets forth the best mode contemplated by me of carrying out the invention; and

THAT I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I HEREBY CLAIM foreign priority benefits under Title 35, United States Code § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number	Country	Foreign Filing Date	Priority Claimed?	Certified Copy Attached?
10-141717	Japan	May 22, 1998	Yes	

I HEREBY CLAIM the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

U.S. Provisional Application Number	Filing Date

I HEREBY CLAIM the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Application Number	Parent Filing Date	Parent Patent Number

I HEREBY APPOINT the following registered attorneys and agents of the law firm of FOLEY & LARDNER:

STEPHEN A. BENT  
 DAVID A. BLUMENTHAL  
 BETH A. BURROUS  
 ALAN I. CANTOR  
 WILLIAM T. ELLIS  
 JOHN J. FELDHAUS  
 PATRICIA D. GRANADOS  
 JOHN P. ISACSON

Reg. No. 29,768  
 Reg. No. 26,257  
 Reg. No. 35,087  
 Reg. No. 28,163  
 Reg. No. 26,874  
 Reg. No. 28,822  
 Reg. No. 33,683  
 Reg. No. 33,715

MICHAEL D. KAMINSKI	Reg. No. 32,904
LYLE K. KIMMS	Reg. No. 34,079
KENNETH E. KROSIN	Reg. No. 25,735
JOHNNY A. KUMAR	Reg. No. 34,649
GLENN LAW	Reg. No. 34,371
PETER G. MACK	Reg. No. 26,001
BRIAN J. MC NAMARA	Reg. No. 32,789
SYBIL MELOY	Reg. No. 22,749
RICHARD C. PEET	Reg. No. 35,792
GEORGE E. QUILLIN	Reg. No. 32,792
BERNHARD D. SAXE	Reg. No. 28,665
CHARLES F. SCHILL	Reg. No. 27,590
RICHARD L. SCHWAAB	Reg. No. 25,479
HAROLD C. WEGNER	Reg. No. 25,258

to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, and to transact all business in the United States Patent and Trademark Office connected therewith.

I request that all correspondence be directed to:

Stephen A. Bent  
 FOLEY & LARDNER  
 Washington Harbour  
 3000 K Street, N.W., Suite 500  
 Washington, D.C. 20007-5109


Telephone: (202) 672-5404  
 Facsimile: (202) 672-5399


I UNDERSTAND AND AGREE THAT the foregoing attorneys and agents appointed by me to prosecute this application do not personally represent me or my legal interests, but instead represent the interests of the legal owner(s) of the invention described in this application.

I FURTHER DECLARE THAT all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1-00

Name of first inventor	<u>Kazuo Kobayashi</u>
Residence	<u>Yokohama-shi, JAPAN</u> JFX
Citizenship	<u>Japanese</u>
Post Office Address	<u>c/o Kiban Gijutsu Kenkyusho, Kirin Beer Kabushiki Kaisha, 1-13-5, Fukuura, Kanazawa-ku, Yokohama-shi, Kanagawa 236-0004 Japan</u>
Inventor's signature	<u>Kazuo Kobayashi</u>
Date	<u>July 6, 2001</u>

Name of second inventor	Makoto Takeuchi
Residence	Yokohama-shi, JAPAN 
Citizenship	Japanese
Post Office Address	c/o Kiban Gijutsu Kenkyusho, Kirin Beer Kabushiki Kaisha, 1-13-5, Fukuura, Kanazawa-ku, Yokohama-shi, Kanagawa 236-0004 Japan
Inventor's signature	
Date	

Name of second inventor's legal representative	<u>Yoriko TAKEUCHI</u>
Relationship with the inventor	<u>wife</u>
Residence	<u>Yokohama-shi, JAPAN</u>
Citizenship	<u>Japanese</u>
Post Office Address	<u>c/o Kiban Gijutsu Kenkyusho, Kirin Beer Kabushiki Kaisha, 1-13-5, Fukuura, Kanazawa-ku, Yokohama-shi, Kanagawa 236-0004 Japan</u>
Legal representative's signature	<u></u>
Date	<u>July 6, 2001</u>

Name of third inventor Akihiko Iwamatsu

Residence Yokohama-shi, JAPAN *TR*

Citizenship Japanese

Post Office Address c/o Kiban Gijutsu Kenkyusho, Kirin Beer Kabushiki Kaisha, 1-13-5,  
Fukuura, Kanazawa-ku, Yokohama-shi, Kanagawa 236-0004 Japan

Inventor's signature *Akihiko Iwamatsu*

Date July 6, 2001

Name of fourth inventor	<u>Kenji Yamamoto</u>
Residence	<u>Otsu-shi, JAPAN</u> <u>JR</u>
Citizenship	<u>Japanese</u>
Post Office Address	<u>9-3, Ohginosato-higashi 6-chome,</u> <u>Otsu-shi, Shiga 520-0248, Japan</u>
Inventor's signature	<u>Kenji Yamamoto</u>
Date	<u>July 6, 2001</u>

5-00

Name of fifth inventor

Hidehiko Kumagai

Residence

Otsu-shi, Japan JPK

Citizenship

Japanese

Post Office Address

32-2, Hiyoshidai 3-chome,  
Otsu-shi, Shiga 520-0112, JAPAN

Inventor's signature

熊谷 英彦

Date

July 6, 2001

6-00

Name of sixth inventor

Satoshi Yoshida

Residence

Yokohama-shi, JAPAN JPY

Citizenship

Japanese

Post Office Address

c/o Kiban Gijutsu Kenkyusho, Kirin Beer Kabushiki Kaisha, 1-13-5,  
Fukuura, Kanazawa-ku, Yokohama-shi, Kanagawa 236-0004 Japan

Inventor's signature

Satoshi Yoshida

Date

July 6, 2001

SEQUENCE LISTING

<110> KIRIN BEER KABUSHIKI KAISHA

<120> Endo-  $\beta$ -N-Acetylglucosaminidase Gene

<130> PH-657-PCT

<140>

<141>

<150> JP98/141717

<151> 1998-05-22

<160> 37

<170> PatentIn Ver. 2.0

<210> 1

<211> 2369

<212> DNA

<213> *Mucor hiemalis*

<400> 1

gtcgaccac gctgccgcg acgcgtgggc ggacgcgtgg gcggacgcgt gggttttatt 60  
ttacataaat atgccttcac ticaattgca acctgatgac aaactagcac ctgtttcttt 120  
tgcacttaag tctatgaatg agttgagga ctggacgcc aacgaaaaga taaagtttaa 180  
cgtttcaagc gtggcactac agcctcgtgt gaaaaacgcc ctgaaacctc aattattgtt 240  
aactcatgat atggcaggag gatataaaga agataaaaat attcaaggaa acaattataa 300

agacatttat aacattcaat attggcattt agctgatact ttgtatatt tctctcatga 360  
 gcgagttagc attcctccag tcaattggac aaatgcttgt catagaaatg gtgtaaaagt 420  
 ttttaggtact ttttttagtag aaggaaataa ccaaatgcac gaaatggaag ccttgcttca 480  
 cgggtccacct ttacttaata acactgacga ccctatgaga ttatggagtc cgtattatgc 540  
 agaccaatta gtgtctattg ctaaacacta tggttttgat ggctggttgt tcaatattga 600  
 atgcgaattc ttctcttttc ctacaaatcc aaaattcaaa gctgaagagt tggcaaaagt 660  
 tctacactat ttttaaggaaa aattgcataa cgaataacct ggatctcaac tcatttggtta 720  
 cgacagcatg acaaatgaag gagaaatcca ctggcagaac cagctccatc ggaaaaatga 780  
 gttatttttt aaaaacacgg atggtatttt ttgtaattat tggtggaata aagaataccc 840  
 tgaaatggcg cgtagagtag ctgaaggaaat aggtagatca ggtttagaag tttatttttg 900  
 tacagatgta tggggaaggc atacttatgg tggcgggtgt ttcaaatcat ataagggtgt 960  
 aaaaactgcc tactctgcga tgacatcttc tgcattattt ggtatggcat ggacatacga 1020  
 gcatttcgaa aagtctgaat ttgaaaagat ggatcgtttg ttttggtgtg gtggttaata 1080  
 ctctgactat cctcccccac ctcttaaaaa ccagatgac gaaaaagaag tagaaagcga 1140  
 tgatagttaa gatgagctca tgtacggaca caagaaaggt attgctgaca cggtagaata 1200  
 tattctctga ccaggaacag attggtttgt taccaatttt gatagggggt ttggaatag 1260  
 gttttattat agaggaaaga gattacttct tcagccttgg tccattttat cgcatacagc 1320  
 tatttcccc aataaaagct atcgaaatcc agagatttat cccactgac aaaacattaa 1380  
 aatcactagt tctctcgatt gcgatcatgg agcttttctt ggtggaacct cgcttattat 1440  
 caaaggccaa cgtttcaatc atagagaatc gcgatgatgt gaaactgaaa ttagtatacc 1500  
 tctgtataag ctctcattag atgctagtaa aggatgctca ttgcgttata tttatagaac 1560  
 tttgttgatg aaagatgtaa agttgacagt agcatgtcac ttttcgttaa aaacaaacga 1620  
 ctcatgtaat ttcttcaagg tatggcagcc agatgaaaat ttctcttttg aatatgatga 1680  
 tggaaatgaga gccactgtta caactgaaaa ttctaccgaa agcagatgct ttttattacg 1740  
 tacaacagaa gaagatacag gagaaaaatga ttggataaca aaaactatta atgtgcctgc 1800  
 gtgtccagaa ggaagtcaat tatacattac aagacttgaa gtgagcgtag tattagatac 1860  
 agctgggtta gtaggtcttg ttaatcaagt tattgcttgc ttgggatata ttagcatcat 1920  
 accaactata aattctggaa taaaaacaga ttcatcacgc attattcagg atctcttttg 1980  
 gaaagatcag aaatatacca aaatcggaag agaaagtta gacgacatag ctcaagaaga 2040

agttcataga tattatggaa cattgaactg ggaaaacaca gcaaatgtag taaacgcttg 2100  
 ggaggaaata gattactaca acgtttttta caaagaaagt gacgactctg caactcgcat 2160  
 ctttttagga acagcattct gtaatcaatt tcgtgtatct ggttagata ttattttatc 2220  
 taagctacca aagatagtta ttgaagctgt taacaaagaa ggatacatct ctccaagtg 2280  
 tagcatagat ttgtcattaa actaggactt gaaataaaat attatgataa agaaaaaaaa 2340  
 aaaaaaaaaa aaaaaaaaaa ggcggccgc 2369

<210> 2

<211> 2235

<212> DNA

<213> *Mucor hiemalis*

<220>

<221> CDS

<222> (1)..(2235)

<400> 2

atg cct tca ctt caa ttg caa cct gat gac aaa cta gca cct gtt tct	48
Met Pro Ser Leu Gln Leu Gln Pro Asp Asp Lys Leu Ala Pro Val Ser	
1 5 10 15	
ttt gca ctt aag tct atg aat gag ttg agg gac tgg acg cca gac gaa	96
Phe Ala Leu Lys Ser Met Asn Glu Leu Arg Asp Trp Thr Pro Asp Glu	
20 25 30	
aag ata aag ttt aac gtt tca agc gtg gca cta cag cct cgt gtg aaa	144
Lys Ile Lys Phe Asn Val Ser Ser Val Ala Leu Gln Pro Arg Val Lys	
35 40 45	
aac gcc ctg aaa cct caa tta ttg tta act cat gat atg gca gga gga	192
Asn Ala Leu Lys Pro Gln Leu Leu Leu Thr His Asp Met Ala Gly Gly	



50	55	60	
tat aaa gaa gat aaa aat att caa gga aac aat tat aaa gac att tat	240		
Tyr Lys Glu Asp Lys Asn Ile Gln Gly Asn Asn Tyr Lys Asp Ile Tyr			
65	70	75	80
aac att caa tat tgg cat tta gct gat act ttt gta tat ttc tct cat	288		
Asn Ile Gln Tyr Trp His Leu Ala Asp Thr Phe Val Tyr Phe Ser His			
85	90	95	
gag cga gtt agc att cct cca gtc aat tgg aca aat gct tgt cat aga	336		
Glu Arg Val Ser Ile Pro Pro Val Asn Trp Thr Asn Ala Cys His Arg			
100	105	110	
aat ggt gta aag tgt tta ggt act ttt tta gta gaa gga aat aac caa	384		
Asn Gly Val Lys Cys Leu Gly Thr Phe Leu Val Glu Gly Asn Asn Gln			
115	120	125	
atg cat gaa atg gaa gcc ttg ctt cac ggt cca cct tta ctt aat aac	432		
Met His Glu Met Glu Ala Leu Leu His Gly Pro Pro Leu Leu Asn Asn			
130	135	140	
act gac gac cct atg aga tta tgg agt ccg tat tat gca gac caa tta	480		
Thr Asp Asp Pro Met Arg Leu Trp Ser Pro Tyr Tyr Ala Asp Gln Leu			
145	150	155	160
gtt gct att gct aaa cac tat ggt ttt gat ggc tgg ttg ttc aat att	528		
Val Ala Ile Ala Lys His Tyr Gly Phe Asp Gly Trp Leu Phe Asn Ile			
165	170	175	
gaa tgc gaa ttc ttt cct ttt cct aca aat cca aaa ttc aaa gct gaa	576		
Glu Cys Glu Phe Phe Pro Phe Pro Thr Asn Pro Lys Phe Lys Ala Glu			
180	185	190	
gag ttg gca aag ttt cta cac tat ttt aag gaa aaa ttg cat aac gaa	624		
Glu Leu Ala Lys Phe Leu His Tyr Phe Lys Glu Lys Leu His Asn Glu			
195	200	205	
ata cct gga tct caa ctc att tgg tac gac agc atg aca aat gaa gga	672		



aaa ggt att gct gac acg gta gaa tct att cct gta cca gga aca gat	1152
Lys Gly Ile Ala Asp Thr Val Glu Ser Ile Pro Val Pro Gly Thr Asp	
370 375 380	
tgg ttt gtt acc aat ttt gat agg ggg ttt gga aat agg ttt tat tat	1200
Trp Phe Val Thr Asn Phe Asp Arg Gly Phe Gly Asn Arg Phe Tyr Tyr	
385 390 395 400	
aga gga aag aga tta ctt tct cag cct tgg tcc cat tta tgc cat caa	1248
Arg Gly Lys Arg Leu Leu Ser Gln Pro Trp Ser His Leu Ser His Gln	
405 410 415	
gct att ctc ccc aat aaa agc tat cga aat cca gag att tat ccc act	1296
Ala Ile Leu Pro Asn Lys Ser Tyr Arg Asn Pro Glu Ile Tyr Pro Thr	
420 425 430	
gat caa aac att aaa atc act agt tct ctc gat tgc gat cat gga gct	1344
Asp Gln Asn Ile Lys Ile Thr Ser Ser Leu Asp Cys Asp His Gly Ala	
435 440 445	
ttt ctt ggt gga acc tgc ctt att atc aaa ggc caa cgt ttc aat cat	1392
Phe Leu Gly Gly Thr Ser Leu Ile Ile Lys Gly Gln Arg Phe Asn His	
450 455 460	
aga gaa tgc cat gat gtt gaa act gaa att agt ata cct ctg tat aag	1440
Arg Glu Ser His Asp Val Glu Thr Glu Ile Ser Ile Pro Leu Tyr Lys	
465 470 475 480	
ctt tca tta gat gct agt aaa gga tgc tca ttg cgt tat att tat aga	1488
Leu Ser Leu Asp Ala Ser Lys Gly Cys Ser Leu Arg Tyr Ile Tyr Arg	
485 490 495	
act ttg ttg atg aaa gat gta aag ttg aca gta gca tgt cac ttt tgc	1536
Thr Leu Leu Met Lys Asp Val Lys Leu Thr Val Ala Cys His Phe Ser	
500 505 510	
tta aaa aca aac gac tca gtt aat ttc ttc aag gta tgg cag cca gat	1584
Leu Lys Thr Asn Asp Ser Val Asn Phe Phe Lys Val Trp Gln Pro Asp	



Val Val Asn Ala Trp Glu Glu Ile Asp Tyr Tyr Asn Val Phe Tyr Lys	
675	680 685
gaa agt gac gac tct gca act cgc atc ttt tta gga aca gca ttc tgt	2112
Glu Ser Asp Asp Ser Ala Thr Arg Ile Phe Leu Gly Thr Ala Phe Cys	
690	695 700
aat caa ttt cgt gta tct ggt tta gat att att tta tct aag cta cca	2160
Asn Gln Phe Arg Val Ser Gly Leu Asp Ile Ile Leu Ser Lys Leu Pro	
705	710 715 720
aag ata gtt att gaa gct gtt aac aaa gaa gga tac atc tct tca agt	2208
Lys Ile Val Ile Glu Ala Val Asn Lys Glu Gly Tyr Ile Ser Ser Ser	
725	730 735
ggt agc ata gat ttg tca tta aac tag	2235
Gly Ser Ile Asp Leu Ser Leu Asn	
740	745

<210> 3

<211> 744

<212> PRT

<213> *Mucor hiemalis*

<400> 3

Met Pro Ser Leu Gln Leu Gln Pro Asp Asp Lys Leu Ala Pro Val Ser	
1	5 10 15
Phe Ala Leu Lys Ser Met Asn Glu Leu Arg Asp Trp Thr Pro Asp Glu	
20	25 30
Lys Ile Lys Phe Asn Val Ser Ser Val Ala Leu Gln Pro Arg Val Lys	
35	40 45
Asn Ala Leu Lys Pro Gln Leu Leu Leu Thr His Asp Met Ala Gly Gly	

50	55	60
Tyr Lys Glu Asp Lys Asn Ile Gln Gly Asn Asn Tyr Lys Asp Ile Tyr		
65	70	75
Asn Ile Gln Tyr Trp His Leu Ala Asp Thr Phe Val Tyr Phe Ser His		
85	90	95
Glu Arg Val Ser Ile Pro Pro Val Asn Trp Thr Asn Ala Cys His Arg		
100	105	110
Asn Gly Val Lys Cys Leu Gly Thr Phe Leu Val Glu Gly Asn Asn Gln		
115	120	125
Met His Glu Met Glu Ala Leu Leu His Gly Pro Pro Leu Leu Asn Asn		
130	135	140
Thr Asp Asp Pro Met Arg Leu Trp Ser Pro Tyr Tyr Ala Asp Gln Leu		
145	150	155
Val Ala Ile Ala Lys His Tyr Gly Phe Asp Gly Trp Leu Phe Asn Ile		
165	170	175
Glu Cys Glu Phe Phe Pro Phe Pro Thr Asn Pro Lys Phe Lys Ala Glu		
180	185	190
Glu Leu Ala Lys Phe Leu His Tyr Phe Lys Glu Lys Leu His Asn Glu		
195	200	205
Ile Pro Gly Ser Gln Leu Ile Trp Tyr Asp Ser Met Thr Asn Glu Gly		
210	215	220
Glu Ile His Trp Gln Asn Gln Leu Thr Trp Lys Asn Glu Leu Phe Phe		
225	230	235
Lys Asn Thr Asp Gly Ile Phe Leu Asn Tyr Trp Trp Lys Lys Glu Tyr		
245	250	255
Pro Glu Met Ala Arg Arg Val Ala Glu Gly Ile Gly Arg Ser Gly Leu		
260	265	270
Glu Val Tyr Phe Gly Thr Asp Val Trp Gly Arg His Thr Tyr Gly Gly		
275	280	285



515	520	525
Glu Asn Phe Ser Phe Glu Tyr Asp Asp Gly Met Arg Ala Thr Val Thr		
530	535	540
Thr Glu Asn Ser Thr Glu Ser Arg Cys Phe Leu Leu Arg Thr Thr Glu		
545	550	555
Glu Asp Thr Gly Glu Asn Asp Trp Ile Thr Lys Thr Ile Asn Val Pro		
565	570	575
Ala Val Pro Glu Gly Ser Gln Leu Tyr Ile Thr Arg Leu Glu Val Ser		
580	585	590
Val Val Leu Asp Thr Ala Gly Leu Val Gly Leu Val Asn Gln Val Ile		
595	600	605
Ala Cys Leu Gly Tyr Ile Ser Ile Ile Pro Thr Ile Asn Ser Gly Ile		
610	615	620
Lys Thr Asp Ser Ser Arg Ile Ile Gln Asp Leu Phe Trp Lys Asp Gln		
625	630	635
Lys Tyr Thr Lys Ile Gly Lys Glu Ser Leu Asp Asp Ile Ala Gln Glu		
645	650	655
Glu Val His Arg Tyr Tyr Gly Thr Leu Asn Trp Glu Asn Thr Ala Asn		
660	665	670
Val Val Asn Ala Trp Glu Glu Ile Asp Tyr Tyr Asn Val Phe Tyr Lys		
675	680	685
Glu Ser Asp Asp Ser Ala Thr Arg Ile Phe Leu Gly Thr Ala Phe Cys		
690	695	700
Asn Gln Phe Arg Val Ser Gly Leu Asp Ile Ile Leu Ser Lys Leu Pro		
705	710	715
Lys Ile Val Ile Glu Ala Val Asn Lys Glu Gly Tyr Ile Ser Ser Ser		
725	730	735
Gly Ser Ile Asp Leu Ser Leu Asn		
740		



<210> 4

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> partial amino acid sequence of endo- $\beta$ -N-acetylglucosaminidase

<400> 4

Pro Ser Leu Gln Leu Gln Pro Asp Asp Lys

1

5

10

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide designed based on the partial amino acid  
sequence of endo- $\beta$ -N-acetylglucosaminidase

<220>

<221> modified\_base

<222> 12

<223> n represents a, g, c or t

<400> 5

carttrcarc cngaygayaa

20

<210> 6

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> partial amino acid sequence of endo- $\beta$ -N-acetylglucosaminidase

<400> 6

Ser Tyr Arg Asn Pro Glu Ile Tyr Pro Thr Asp Gln Asn Ile Lys

1

5

10

15

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide designed based on the partial amino acid  
sequence of endo- $\beta$ -N-acetylglucosaminidase

<220>

<221> modified\_base

<222> 6

<223> n represents a, g, c or t

<400> 7

cchacngayc araayatya

20

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide designed based on the partial amino acid  
sequence of endo- $\beta$ -N-acetylglucosaminidase

<220>

<221> modified\_base

<222> 15

<223> n represents a, g, c or t

<400> 8

ttratrtyt grtcngtdgg

20

<210> 9

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> partial amino acid sequence of endo- $\beta$ -N-acetylglucosaminidase

<400> 9

Gly Gln Arg Phe Asn His Arg Glu Ser His Asp Val Glu Thr Glu Ile

1

5

10

15

<210> 10

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide designed based on the partial amino acid  
sequence of endo- $\beta$ -N-acetylglucosaminidase

<400> 10

tgrttraadc gytgdccytt

20

<210> 11

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide sequence of 5' terminal region of

endo- $\beta$ -N-acetylglucosaminidase gene

<400> 11

atgccttcac ttcaattgca acc

23

<210> 12

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide sequence of 3' terminal region of  
endo- $\beta$ -N-acetylglucosaminidase gene

<400> 12

ctagttaaat gacaaatcta tgc

23

<210> 13

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide designed based on the sequence of  
endo- $\beta$ -N-acetylglucosaminidase gene

<400> 13

cacttaagtc tatgaatgag

20

<210> 14

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide designed based on the sequence of  
endo- $\beta$ -N-acetylglucosaminidase gene

<400> 14

aatctctgga ttctgatagc

20

<210> 15

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide designed based on the sequence of  
endo- $\beta$ -N-acetylglucosaminidase gene

<400> 15

ggggcggccg cttttatattt acataaatat gcccttcactt c

41

<210> 16

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide designed based on the sequence of  
endo- $\beta$ -N-acetylglucosaminidase gene

<400> 16

cccgcggcgcg cctagtttaa igacaaatct atgctacc

38

<210> 17

<211> 10

<212> PRT

<213> *Mucor hiemalis*

<400> 17

Pro Ser Leu Gln Leu Gln Pro Asp Asp Lys

1

5

10

<210> 18

<211> 16

<212> PRT

<213> *Mucor hiemalis*

<400> 18

Lys Ser Tyr Arg Asn Pro Glu Ile Tyr Pro Thr Asp Gln Asn Ile Lys  
 1 5 10 15

<210> 19

<211> 14

<212> PRT

<213> Mucor hiemalis

<400> 19

Lys Phe Asn Val Ser Ser Val Ala Leu Gln Pro Arg Val Lys  
 1 5 10

<210> 20

<211> 11

<212> PRT

<213> Mucor hiemalis

<220>

<221> PEPTIDE

<222> 2

<223> Xaa represents Met or Ser

<400> 20

Lys Xaa Asp Arg Leu Phe Leu Cys Gly Gly Lys  
 1 5 10



<210> 21

<211> 17

<212> PRT

<213> Mucor hiemalis

<220>

<221> PEPTIDE

<222> 2

<223> Xaa represents Gly or Met

<220>

<221> PEPTIDE

<222> 3

<223> Xaa represents Gln or Ala

<220>

<221> PEPTIDE

<222> 4

<223> Xaa represents Arg or Leu

<220>

<221> PEPTIDE

<222> 6

<223> Xaa represents Asn or Pro

<220>

<221> PEPTIDE

<222> 8

<223> Xaa represents Arg or Leu

<220>

<221> PEPTIDE

<222> 9

<223> Xaa represents Glu or Leu

<220>

<221> PEPTIDE

<222> 10

<223> Xaa represents Ser or Leu

<220>

<221> PEPTIDE

<222> 11

<223> Xaa represents His or Thr

<400> 21

Lys Xaa Xaa Xaa Phe Xaa His Xaa Xaa Xaa Xaa Asp Val Glu Thr Glu

1

5

10

15

Ile

<210> 22

<211> 16

<212> PRT

<213> Mucor hiemalis

<400> 22

Lys Glu Gly Tyr Ile Ser Ser Ser Gly Ser Ile Asp Leu Ser Leu Asn

1

5

10

15

&lt;210&gt; 23

&lt;211&gt; 9

&lt;212&gt; PRT

<213> *Mucor hiemalis*

&lt;400&gt; 23

Lys Asn Ile Gln Gly Asn Asn Tyr Lys

1

5

&lt;210&gt; 24

&lt;211&gt; 11

&lt;212&gt; PRT

<213> *Mucor hiemalis*

&lt;400&gt; 24

Lys Tyr Ser Asp Tyr Pro Pro Pro Pro Pro Lys

1

5

10

&lt;210&gt; 25

&lt;211&gt; 8

&lt;212&gt; PRT

<213> *Mucor hiemalis*

&lt;400&gt; 25

Lys Leu Ser Leu Asp Ala Ser Lys

1

5

<210> 26

<211> 13

<212> PRT

<213> Mucor hiemalis

<400> 26

Lys Asn Thr Asp Gly Ile Phe Leu Asn Tyr Trp Trp Lys

1

5

10

<210> 27

<211> 15

<212> PRT

<213> Mucor hiemalis

<220>

<221> PEPTIDE

<222> 3

<223> Carboxymethylcystein

<400> 27

Lys Gly Cys Ser Leu Arg Tyr Ile Tyr Arg Thr Leu Leu Met Lys

1

5

10

15

<210> 28

<211> 7

<212> PRT

<213> Mucor hiemalis

<220>

<221> PEPTIDE

<222> 6

<223> Carboxymethylcystein

<400> 28

Lys Leu Thr Val Ala Cys His

1

5

<210> 29

<211> 15

<212> PRT

<213> Mucor hiemalis

<400> 29

Lys Pro Gln Leu Leu Leu Thr His Asp Met Ala Gly Gly Tyr Lys

1

5

10

15

<210> 30

<211> 14

<212> PRT

<213> Mucor hiemalis

<400> 30

Lys Ser Met Asn Glu Leu Arg Asp Trp Thr Pro Asp Glu Lys

1 5 10

<210> 31

<211> 10

<212> PRT

<213> *Mucor hiemalis*

<400> 31

Lys Leu Ala Pro Val Ser Phe Ala Leu Lys

1 5 10

<210> 32

<211> 23

<212> PRT

<213> *Mucor hiemalis*

<400> 32

Lys Gly Gln Arg Phe Asn His Arg Glu Ser His Asp Val Glu Thr Glu

1 5 10 15

Ile Ser Ile Pro Leu Tyr Lys

20

<210> 33

<211> 22

<212> PRT

<213> *Mucor hiemalis*

<220>

<221> PEPTIDE

<222> 8

<223> Carboxymethylcystein

<400> 33

Lys Ile Thr Ser Ser Leu Asp Cys Asp His Gly Ala Phe Leu Gly Gly

1 5 10 15

Thr Ser Leu Ile Ile Lys

20

<210> 34

<211> 19

<212> PRT

<213> *Mucor hiemalis*

<400> 34

Lys Asn Glu Leu Phe Phe Lys Asn Thr Asp Gly Ile Phe Leu Asn Tyr

1 5 10 15

Trp Trp Lys

<210> 35

<211> 9

<212> PRT

<213> *Mucor hiemalis*

<400> 35

Lys Ile Val Ile Glu Ala Val Asn Lys

1

5

<210> 36

<211> 11

<212> PRT

<213> *Mucor hiemalis*

<400> 36

Ser Ser Arg Ile Ile Gln Asp Leu Phe Trp Lys

1

5

10

<210> 37

<211> 14

<212> PRT

<213> *Mucor hiemalis*

<400> 37

Lys Thr Asp Ser Ser Arg Ile Ile Gln Asp Leu Phe Trp Lys

1

5

10